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Decreasing estrogen levels, associated with menopause, may cause several unpleasant 
symptoms.  Hormone replacement therapy (HRT) relieves these symptoms, but increases the risk 
of developing breast cancer. As estrogens promote estrogen-receptor positive (ER
+
) breast 
cancer, women are seeking alternative forms of hormone therapy and are turning to plant-based 
products high in phytoestrogens, since they are considered to be a more natural, healthier and 
potentially safer alternative to HRT. Another alluring aspect of plant-based products are their 
ability to exert their effect through multiple target mechanisms, which is potentially due to the 
complex mixture of different bio-active and supporting compounds working together. The 
current study forms part of a larger ongoing study, which focuses on Cyclopia, an indigenous 
South African fynbos plant, as a potential nutraceutical to reduce menopausal symptoms, while 
decreasing the risk of breast cancer. The sequential methanol extract of Cyclopia subternata 
(SM6Met) displayed promising results in different in vitro and in vivo breast cancer experimental 
systems, with the desired estrogenic characteristics of ER subtype selectivity, specifically ERβ 
agonism and ERα antagonism (which is important in ER
+ 
breast cancer since ERα is known to 
induce proliferation, whereas ERβ antagonises ERα), and the inhibition of estrogen-induced 
breast cancer cell proliferation. However, the compounds responsible for the desired estrogenic 
characteristics have not been identified and thus, as a starting point, we focused on the 7 major 
phenolic compounds quantified in a fraction, F3, obtained from SM6Met. F3 previously 
displayed robust ERβ agonism, and the aim of the current study was thus to evaluate the 
combinatorial effect of these 7 major phenolic compounds to the favourable estrogenic profile of 
F3. Firstly, an experimental system sensitive enough to detect small drug induced changes was 
successfully established, after which the phytoestrogenic activity of the 7 major phenolic 
compounds were tested individually and in combination. Interestingly, the reconstituted faction 
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(F3R), in contrast to F3, displayed no significant estrogenic activity when the 7 major phenolic 
compounds were reconstituted at a concentration equivalent to that which is present in F3. 
However, when F3R was reconstituted at 100-fold its concentration, a significant increase in 
activity was observed via both ER subtypes. Mangiferin and luteolin were the only two phenolic 
compounds that displayed significant and dose-dependent l estrogenic activity when tested alone. 
Since, at this stage of the study, not much was known regarding the estrogenicity of mangiferin, 
a more in detailed investigation revealed activity via ERα and also, as a novel finding, via ERβ.  
The current study concluded that F3’s robust ERβ agonist activity could not be recreated using 
only the 7 major phenolic compounds at their concentration in F3 but that the minor phenolic 
compounds play a crucial supporting role in the desired estrogenic profile of this fraction. Thus, 
the contribution of the 7 major phenolic compounds to F3’s activity, and subsequently the multi-
target activity of SM6Met, should not be dismissed, since other compounds present in F3, but not 
in F3R, may act synergistically with the major phenolic compounds to produce the robust ERβ 
activity of F3. 
  




Die vermindering van estrogeenvlakke, wat met menopouse gepaard gaan, kan verskeie 
onaangename simptome veroorsaak. Hormoon-vervangingsterapie (HVT) verlig hierdie 
simptome, maar verhoog die risiko om borskanker te ontwikkel. Aangesien estrogeen-reseptor 
positiewe (ER
+
) borskanker deur estrogeen bevorder word, soek vrouens alternatiewe vorme van 
hormoonterapie en wend hulle na plantgebaseerde produkte wat hoog is in fitoestrogene, 
aangesien fitoestrogene beskou word as 'n meer natuurlike, gesonder en potensieel veiliger 
alternatief teenoor HVT. Nog 'n aanloklike aspek van plantgebaseerde produkte is hul vermoë 
om hul effek uit te oefen deur verskeie teiken meganismes, wat moontlik te wyte is aan die 
komplekse mengsel van verskillende bio-aktiewe en ondersteunende verbindings wat saamwerk. 
Die huidige studie vorm deel van 'n groter deurlopende studie wat fokus op Cyclopia, 'n 
inheemse Suid-Afrikaanse fynbosplant, as 'n potensiële nutraceutiese middel om menopousale 
simptome te verminder, terwyl die risiko van borskanker verlaag word. Die sekwensiële metanol 
ekstrak van Cyclopia subternata (SM6Met) het belowende resultate in verskeie in vitro en in 
vivo borskanker eksperimentele stelsels getoon, met die gewensde estrogeen eienskappe van ER 
subtypeselektiwiteit, spesifiek ERβ-agonisme en ERα-antagonisme (wat belangrik is in ER
+
 
borskanker, aangesien ERα bekend is om proliferasie te bewerkstellig, terwyl ERβ vir ERα 
antagoniseer) en die inhibisie van estrogeen-geïnduseerde borskanker proliferasie. Die 
verbindings wat verantwoordelik is vir die gewensde estrogeen eienskappe is egter nog nie 
geïdentifiseer nie, en dus as ‘n begin punt, word daar gefokus op die 7 hoof fenoliese verbindings 
wat gekwantifiseer is in 'n fraksie, F3, verkry uit SM6Met. F3 het voorheen robuuste ERβ-
agonisme getoon, en die doel van die huidige studie was dus om die kombinatoriese effek van 
hierdie 7 hoof fenoliese verbindings te evalueer op die gunstige estrogeenprofiel van F3. 
Eerstens was 'n eksperimentele stelsel daargestel wat sensitief genoeg is om klein middel-
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geïnduceerde veranderings suksesvol op te tel, waarna die fitoestrogeen aktiwiteit van die 7 hoof 
fenoliese verbindings individueel en in kombinasie getoets is. Interessant genoeg, het die 
hersaamgestelde fraksie (F3R), in teenstelling met F3, geen beduidende estrogeen aktiwiteit 
getoon nie toe die 7 hoof fenoliese verbindings gekombineer is by 'n konsentrasie gelykstaande 
aan wat in F3 teenwoordig is. Toe F3R egter teen 100-voudige konsentrasie hersaamgestel is, is 
'n beduidende toename in aktiwiteit waargeneem via beide ER subtipes. Mangiferin en luteolin 
was die enigste twee fenoliese verbindings wat beduidende en dosis afhanklike estrogeen 
aktiwiteit getoon het toe hulle alleen getoets is. Aangesien daar op hierdie stadium van die studie 
nie veel bekend was omtrent die estrogenisiteit van mangiferin nie, het 'n meer gedetailleerde 
ondersoek aktiwiteit via ERα, en ook as 'n nuwe bevinding via ERβ, aan die lig gebring. Die 
huidige studie het tot die gevolgtrekking gekom dat F3 se robuuste ERβ-agonistiese aktiwiteit 
nie herskep kon word deur slegs die 7 hoof fenoliese verbindings by hul konsentrasie in F3 te 
gebruik nie, maar dat die ander fenoliese verbindings 'n belangrike ondersteunings rol speel in 
die gewenste estrogeenprofiel van hierdie fraksie. Dus, moet die bydrae van die 7 hoof fenoliese 
verbindings tot F3 se aktiwiteit, en die daaropvolgende multi-doelaktiwiteit van SM6Met, nie 
gering geskat word nie, aangesien ander verbindings teenwoordig in F3, maar nie in F3R, 
sinergisties mag optree met die hoof fenoliese verbindings om die robuuste ERβ aktiwiteit van 
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H-E2     Tritiated 17-β estradiol 
2-AAF     2-acetylaminofluorene 
ABTS•+    2,2′-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid 
AD     anno Domini 
AF-1     Activation function-1 
AIDS     Acquired Immune Deficiency Syndrome 
ANOVA    Analysis of variance 
AOM     Azoxymethane 
BC      Before Christ 
BRCA     Breast Cancer 
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DBD     DNA binding domain 
DMEM    Dulbecco’s modified Eagle’s medium 
DMSO     Dimethyl sulfoxide 
DNA     Deoxyribonucleic acid 
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E1     Estrone 
E2     17-β Estradiol 
E3     Estriol 
EAc     Ethyl acetate 
ECL     Enhanced chemiluminescence 
EDTA     Ethylenediaminetetra-acetic acid 
EGFR     Epidermal growth factor receptor 
ER     Estrogen receptor 
ER
+     
Estrogen receptor positive 
ERα     Estrogen receptor alpha 
ERβ     Estrogen receptor beta 
ERE     Estrogen response element 
ERK     Extracellular signal-regulated kinase 
ERm     Membrane-bound estrogen receptor 
ESI     Electrospray ionization 
Eth/EtOH    Ethanol 
F1     Fraction 1 
F2     Fraction 2 
F3     Fraction 3 
F3R     Reconstituted Fraction 3  
FCS     Fetal calf serum 
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Estrogens are steroid hormones that play an important role in the development, functioning 
and maintenance of various systems including the reproductive, immune, musculoskeletal, 
cardiovascular, and central nervous system [1–6]. The different endogenous estrogens: 
estrone (E1), estradiol (E2) and estriol (E3), have tissue specific roles and their concentrations 
in the female body vary during different stages of a woman’s life (puberty, menstrual cycle, 
pregnancy and menopause), with E2 being the most abundant and potent estrogen [3,7–15]. 
Therefore, a decrease in endogenous estrogens, associated with the onset of menopause, 
causes many unpleasant vasomotor symptoms such as hot flashes and night sweats, and could 
also lead to the development of osteoporosis, cardiovascular diseases, mental diseases such as 
Schizophrenia and Alzheimer’s disease, and strokes [4,15–21]. 
Hormone replacement therapy (HRT) was for many years considered to be the best treatment 
for menopausal symptoms and related diseases, until numerous clinical studies showed that 
the intake of exogenous or synthetic estrogens have various risks and side effects, including, 
but not limited to, weight gain, irregular bleeding, headaches, breast tenderness and pain, 
depression, and  the promotion of estrogen-related cancers such as breast cancer [15,22–29]. 
Breast cancer is the most common occurring cancer in women, and although breast cancer 
statistics vary between different population groups, ethnic groups and ages, this epidemic has 
a social and economic impact on both developed and developing countries [25,30–40]. South 
Africa is no exception, with breast cancer ranking top of the list of cancers among South 
African women [41,42]. According to the Cancer Association of South Africa (CANSA), the 
lifetime risk of developing breast cancer for South African women of all races average 1 in 
every 29 [43]. Estrogen receptor (ER) positive breast cancer is the most common type of 
breast cancer, and many of the risk factors associated with ER positive breast cancer (obesity, 
early menarche, the use of hormone contraceptives, late birth of first child, late menopause) 
are linked to estrogens [30,44–47]. Also, with a higher occurrence of breast cancer after the 
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age of 50, women are seeking safer alternatives for the treatment of menopausal symptoms 
and related diseases, with reduced risk of developing breast cancers [30,32,48–51].  
Estrogens (endogenous and exogenous) mediate their intracellular effects through the two 
ER’s, ERα and ERβ [6,52,53]. The amino acid sequence difference in the structural (A to F 
region) and functional (DNA binding, ligand binding, AF-1 and AF-2) domains between ERα 
and ERβ indicate that these two receptors have different physiological functions [52–55]. 
ERα is known to induce cell proliferation, whereas ERβ has shown anti-proliferative activity 
by antagonising ERα [55–58]. Most therapeutic targets for estrogen related diseases, such as 
breast cancer, focus on compounds that mediate their effects directly or indirectly through 
ERα [52,54,59,60]. Specifically, for breast cancer, the current hormonal therapy for ER 
positive breast cancer focuses on tamoxifen (a selective estrogen receptor modulators 
(SERM)) as 1
st
 line of therapy, and fulvestrant (a full ER antagonist) as a follow up therapy 
when tamoxifen fails [60–65]. However, the current therapies for breast cancer have side 
effects and often result in therapy resistance. Thus, new therapeutic targets are needed [65–
68]. ERβ is considered an eligible molecular target due to the ‘yin yang’ relationship that 
ERα and ERβ display and, therefore, compounds that mediate their effects via ERβ 
(potentially inhibiting ERα), are of great interest in novel ER related therapy development 
[57,68–70].  
Plant-based products high in phytoestrogens (e.g. soy or red clover) are considered to be a 
more natural, healthier and potentially safer alternative to HRT [71]. Phytoestrogens are 
structurally similar to endogenous estrogen, and therefore, can exert an estrogenic and/or 
anti-estrogenic effect directly or indirectly via the ERs [72–75]. Many phytoestrogens have 
been shown to mediate their effect through ERβ, making these compounds desirable as novel 
phytoestrogenic nutraceuticals [68,74,76,77]. Various studies have also linked plant extracts 
and plant-based diets to lower prevalence of cancer, including breast cancer, and they have 
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been shown to have protective properties against osteoporosis, type II diabetes, 
cardiovascular-, immune-, and neurological diseases [71,78–87]. 
Combination therapies using different phytocompounds have also been shown to be more 
effective in treating complex diseases, such as cancer, compared to single active 
phytocompounds, suggesting that the mixture of compounds interact in an additive or 
synergistic manner to elicit a multi-target mode of action [88–94]. The higher effectiveness of 
medicinal plants and plant extracts is thought to be due to the complex mixture of different 
(active and supporting) phytocompounds, with the supporting compounds contributing to the 
stability, solubility, bioavailability, absorption and/or potency of the active compounds 
[87,92,95,96]. However, plant extracts and plant products still need to be used with caution, 
since the phytochemical interactions and the molecular mechanisms of all the different 
phytocompounds are not as well studied as single active compounds or synthetic drugs 
[97,98].   
The current study forms part of a larger ongoing study, which focuses on Cyclopia, an 
indigenous South African fynbos plant that has displayed nutraceutical potential with 
phytoestrogenic, anti-mutagenic, anti-inflammatory and anti-diabetic activity [99–105]. A 
decade of Cyclopia work has been conducted within our research group, initiated by a study 
done by Verhoog et al. [106,74,100], who investigated the phytoestrogenic activity of 
different Cyclopia species: C. intermedia, C. sessiliflora, C. genistoides and C. subternata, 
with the latter two species displaying the highest phytoestrogenic activity. In addition, 
Mfenyana et al. [107], investigated different harvestings of C. genistoides and C. subternata. 
The air-dried dichloromethane plant extracts were prepared in three different ways: 
sequential extracts (S), non-sequential extracts (N) and cup-of-tea extracts, and five solvents 
were used based on polarity differences: ethyl acetate (EAc), ethanol (Eth), methanol (Met), 
50% methanol–distilled water (Hlf) and distilled water (Wat). The sequential methanol 
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extract from C. subternata harvesting M6 (SM6Met) produced both high yield and high 
phytoestrogenic potency in the different experimental systems (promoter-reporter assay, 
whole cell ER-binding, alkaline phosphatase activity and E-screen) used in the study 
[107,108]. Furthermore, in a study by Visser et al., SM6Met displayed ERα antagonism, ERβ 
agonism, and inhibition of E2-induced breast cancer cell proliferation in vitro, as well as ERα 
antagonism in vivo by delaying ERα induced uterine growth in an immature rat uterotrophic 
model [109,105,81]. These favourable estrogenic attributes of SM6Met led to an in vivo study 
by Visser et al. where SM6Met reduced tumour frequency, mass and volume in a N-Methyl-
N-nitrosourea (MNU)-induced rat mammary gland carcinogenesis model [105].  
To fully evaluate SM6Met’s multi-target mode of action, the extract was fractionated and the 
contribution of all the fractions of SM6Met to its favourable estrogenic attributes was 
investigated. Specifically, SM6Met was fractionated by Mortimer et al. [90,110], using 
liquid-liquid fractionation to obtain a polar fraction (PF) and a non-polar fraction (NPF), with 
the NPF retaining all the favourable estrogenic attributes of SM6Met. The NPF was then 
fractionated into 3 fractions (F1, F2 and F3) using high performance counter-current 
chromatography (HPCCC) and the phenolic content of these fractions were identified and 
quantified with liquid chromatography tandem mass spectrometry (LC-MS/MS) and 
quantitative HPLC, respectively. SM6Met’s favourable estrogenic profile was, however, 
divided between the fractions with F1 and F2 displaying ERα antagonism and F3 displaying 
robust ERβ agonism. Further research is needed to understand how the different phenolic 
compounds in each fraction contribute to that fraction’s favourable estrogenic profile. 
The current study continues on from Mortimer’s findings and focusses on F3, since 
compounds that mediate their activity via ERβ, and subsequently inhibit ERα activity, are of 
great interest in novel treatment development for estrogen-related diseases [56,57,68,76]. 
Mortimer identified 15 phenolic compounds in F3, however, only 7 of these compounds were 
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quantified [90]. The main focus of the current study is to investigate the combinatorial or 
possible synergistic contribution of these 7 major phenolic compounds in F3 to the 
favourable estrogenic profile of F3.  
The Aims of the current study therefore are to:  
1. Develop an estrogenic assay with increased sensitivity to detect compound-induced 
changes, and subsequently establish higher accuracy when investigating the interaction 
of compounds and possible synergism.   
2. Reconstitute F3 (F3R) using only the 7 major phenolic compounds (mangiferin, 
isomangiferin, luteolin, scolymoside, iriflophenone-3-C-glucoside, protocatechuic acid 
and p-coumaric acid) as a starting point to investigate their contribution to F3’s activity.  
3. Investigate the estrogenic activity of the individual phenolic compounds in F3R to 
establish which of the compounds are the active estrogenic compounds.  
4. Use addition and subtraction studies to investigate the supporting role of the non-
estrogenic phenolic compounds in the estrogenic activity of F3R. 
5. Investigate combinatorial or synergistic activity of the estrogenic phenolic compounds 
using a fixed ratio isobologam.  
The remainder of the dissertation consists of five chapters. The literature review (Chapter 2) 
will touch on the history and evolution of traditional and modern medicine, the limitations of 
modern medicine in combating complex multifaceted diseases, such as cancer, and the future 
of phytomedicine and intelligent drug mixtures. Furthermore, an overview of the molecular 
mechanisms and related pathways of phytocompounds, specifically phytoestrogens, will be 
discussed. The literature review will also include a section on Cyclopia and related 
phytocompounds used in the current study. In addition, the literature review will elaborate on 
the concept of synergism, including the advantages of synergism in therapy development and 
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methods to determine combinatorial or synergistic drug interactions. Chapter 3 contains the 
materials and methods used in the current study. Chapter 4 addresses Aim 1 and focusses on 
the optimisation and validation of two in vitro experimental systems, the cell proliferation 
assay in MCF-7 BUS cells and promoter reporter studies in HEK293 cells, with the purpose 
of establishing an experimental system with increased sensitivity, which is especially 
important when testing drug interactions and possible synergism. Chapter 5 addresses Aims 
2-5, and discusses the limitations of the current study including the susceptibility of phenolic 
compounds and tissue culture systems to external changes. The last chapter (Chapter 6) 
contextualise the results from the current study into the bigger scope of phytomedicine and 
addresses future work. 
With the current findings being but a small piece of a larger puzzle, investigating the 
contribution of the 7 major phenolic compounds in F3 will provide insight into the desired 
ERβ agonist activity of this fraction and reveal the complexity of the combinatorial activity 
of plant extracts.  
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Chapter 2: Literature Review 
  




2.1. Introduction  
Plants have for centuries played a vital role in human health and wellbeing, not only as a 
source of shelter and food, but also for the treatment of various ailments and diseases [1–5]. 
Ancient civilisations developed phytomedical systems by observing nature and using a trial 
and error approach, through which they determined whether a plant was beneficial or toxic 
[1–3]. Some of these findings were documented and the knowledge passed on from 
generation to generation [6–11]. Ancient phytomedicine
*
 has formed the foundation upon 
which modern medicine is built, contributing to the discovery and development of numerous 
drugs [1–3,5,12–14].  
The last few decades, medical and scientific research have made great strides in 
understanding the dynamics of health and the mechanisms of disease [15–18]. This increase 
in biological knowledge revealed the complexity of the human body, the fragility of its 
various intricate systems, and identified the multiple contributing factors which builds and 
shapes our physiological composition as humans [15–20].  
As drug development progressed, the main focus shifted from using whole plant extracts 
towards identifying active ingredients, investigating their mechanisms of action, and using 
these active ingredients to our advantage in the fight against complex diseases, such as cancer 
[13,21,22]. But with new found information and techniques, came new challenges such as 
drug resistance, dangerous side effects and decreased drug efficacy, and this method of 
reductionism (as it is referred to in an interesting review article by Corning [16]), was 
revealed not to be the ideal approach in treating complex diseases [23–27].   
                                                 
*
 Phytomedicine is also known as botanic medicine, herbal medicine or ethnomedicine [56,167,168] 




The current study falls within the bigger scope of re-discovering the medicinal power of 
plants and whole plant extracts, since combination therapies, inspired by the unique mixture 
of phytocompounds in medicinal plants, have been shown to be more effective than mono-
therapies in combating complex or multifaceted diseases [28–33]. To narrow it down, the 
current study will focus on one specific plant of interest, Cyclopia, and its medicinal potential 
for combating estrogen related diseases, such as breast cancer. This indigenous South Africa 
plant has shown a variety of disease fighting properties, but the main interest of the current 
study is the phytoestrogenic activity of Cyclopia. 
This literature review is divided into 5 sections: (1) the history and evolution of 
phytomedicine, (2) the concept of synergism (with specific reference to phytomedicine), (3) 
Cyclopia, (4) mechanism of action of phytoestrogens (with specific reference to the estrogen 
signalling pathway) and lastly (5) the major phenolic compounds in the Cyclopia SM6Met 
fraction. 
2.2. History and evolution of phytomedicine 
2.2.1. Ancient traditional medicine 
The history of medicine is as old as mankind itself, and the earliest form of medicine was 
derived mainly from plants [3,4,9,34]. During pre-historical times, not much was known 
about the human body, and pre-historical civilisations relied strongly on nature, as well as 
their different religious/belief systems, for the treatment of various ailments and diseases  
[5,34]. Some cultures believed that diseases were caused by higher powers or spirits, and 
plants were not only used for treating physical ailments, but also in spiritual healing rituals 
[3,9,35–37].  




A B C 
Some of the oldest documentations of medicinal plants stem from ancient Egyptian, 
Mesopotamian and Greek traditions dating back to the 1600 BC (Figure 2.1) [9,37]. Clay 
tablets, scrolls and papyri gave insight into the herbal medicine used by these ancient groups, 
along with their discoveries regarding pathophysiology and the human anatomy [35,38,39]. A 
more rational approach to medicine arose and medical practices focused on the observation of 
symptoms and visible abnormalities, such as examining body fluids, listening to respiratory 
function and observing skin discoloration [35,38–40]. The Mesopotamians had two types of 
medical practitioners, the ashipu, who was responsible for diagnosis of ailments, and the asu, 
who was the specialist in herbal remedies [35]. The Egyptians were also considered to be 
excellent herbalists and the Ebers papyrus (dating from 1500 BC) contains 877 recipes and 
prescriptions for internal medicine, as well as skin and eye problems [3,39–41].  
Figure 2.1: Demonstrations and documentations of ancient medicinal practices. (A) 
representation of a Mesopotamian medical practitioner, (B) fragment of Ebers Papyrus, and (C) 
monks processing and weighing herbs  [35,37]. 
Furthermore, other traditional medical systems that arose independently in different parts of 
the world also had medicinal plants forming the centre of their medical practices. Some of 
these traditional medical systems include: traditional Chinese medicine (TCM) used in parts 
of Asia, Ayurveda used in parts of India, Native American traditional medicine used in North 
America, and different local systems in Africa (which strongly depends on demographic and 
different cultural beliefs) [2,5,8,41,42].  
Ancient Chinese and Indian medicines had a more holistic approach to health and disease 
than the Egyptian, Mesopotamian and Greek systems, but were also known for their 




extensive use of plant-based products [40,43]. They believed that disease was a result of an 
imbalance between the mind, body and spirit, and in order to restore balance and harmony, 
they used herbal remedies combined with physical and spiritual practices such as yoga, 
meditation and acupuncture [2,43]. The ancient texts of Veda describe the earliest use of 
medicinal plants in Ayurvedic medicine [2]. Likewise, the Chinese medicinal book, Wu Shi 
Er Bing Fang, consists of a list of approximately 250 natural agents and 150 combinatorial 
formulations for disease treatment [40]. Although ancient African traditional medicine 
(excluding traditional Egyptian medicine) is not as well documented compared to ancient 
phytomedicine from Europe and Asia, it is considered to be the most diverse of all medicine 
systems with influences from a variety of different cultures within Africa [2,44]. 
Since ancient times, various phytomedicinal books and manuscripts were published, 
describing and categorising the medicinal use of certain plants [35,37,38]. Dioscorides wrote 
the book, De Materia Medica (circa 77AD), wherein he categorised plants according to their 
physical appearance, locality, method of preparation, and medicinal properties [9,37,41]. His 
work provided the foundation for pharmacognosy, the study of drugs originating from plants 
or natural products [9,41]. Other examples of phytomedical books written during the middle 
ages included Avicenna (980-1037), Herbarium Apuleius (480-1050), The Leech Book of 
Bald (925), Physicians of Myddvai (1250), Herbal (Brunfels), Herbal (Brock) and Herbal 
(Mattioli) (1500-1577) [35,37]. There was, however, still a gap in knowledge regarding the 
plant’s active components, mode of actions and the potential side effects the use of medicinal 
plants may have over time.  





 century provided the stepping stones for modern medicine with the 
discovery of various physiological structures and functions (e.g. circulation of blood), the 




increase in theoretical knowledge regarding diseases such as scurvy, rabies and smallpox,  the 
introduction of opium and digitalis (from poppy seeds and foxgloves, respectively), and the 
invention of the microscope [3,5,35,38,45]. The field of pharmacognosy was also established 
during this period, since the demand for compound drugs increased [9,35,41]. Since the 18
th
 
century, phytomedicine moved in a more scientific systematic direction in order to identify 
active compounds and avoid past problem such as toxicity [40].   





century. Progress during this period include the introduction of diagnostic techniques and 
new medical tools (X-ray, stethoscope, thermometer, ophthalmoscope and laryngoscope), 
better understanding of and novel detection methods for diseases such as cholera, 
tuberculosis, diphtheria and typhoid, isolation of alkaloids and glycosides from plants, as well 
as discovery of active substances such as tannins, vitamins, saponosides and etheric oils 
[38,41,46,47].  
As medicine and related techniques evolved, so did the use of medicinal plants, and the focus 
shifted from using whole plant extracts to identifying and isolating active compounds in 
medicinal plants. Past challenges and gaps in phytomedicine knowledge opened up research 
opportunities, and evidence based research became the pioneers of drug development [45]. 
The 20
th
 century was also marked as the beginning of the modern pharmaceutical industry, 
with the introduction of various synthetic versions of natural products [3,38,45]. 
The continued progress of modern medicine in the 21
st
 century was reinforced by the 
improvements of high-tech screening and analytical methods such as high-performance liquid 
chromatography (HPLC), mass spectrometry (MS), and nuclear magnetic resonance (NMR), 
which, together with collaborations from various scientific fields including genomics, 
proteomics, metabolomics and bioinformatics, accelerated the identification, characterisation 




and isolation of active compounds from medicinal plants [48–50]. However, in the beginning 
of the 21
st
 century, most pharmaceutical companies moved away from natural products in 
favour of combinatorial and synthetic chemistry, which were able to reduce the development 
time of drugs as well as the complexity of the drugs developed, and provide a more 
comprehensive understanding of drug interactions [50,51].  
Despite the scientific advances made in drug discovery, 25% of current modern drugs still 
originate directly or indirectly from medicinal plants, showing that plants continue to play an 
important role in the development of modern medicine [49,52]. In addition, during the last 
decade a gradual shift was observed from mono-drug therapies to multi-target therapies and 
multi-drug combinations, with an increased use of traditional and non-conventional medicine 
incorporated into modern medical practices [1,53–56]. A review article by Li et al.[57], refers 
to this transition as the Easternization of Western medicine, and proposes that this shift may 
help discover novel drug interactions and bridge the gap between traditional and modern 
medicine.  
2.2.3. Traditional medicine in the 21st century 
Looking back on how medicine has changed and evolved over time, it is apparent that 
medicinal plants and traditional knowledge have formed the foundation of modern medicine, 
and that even with the strides made in the medical and pharmaceutical industry, 65-80% of 
rural communities worldwide (predominantly in India, China, Africa and parts of South 
America) still rely on traditional medicine and medicinal plants as their primary source of 
health care [44,50,51,57–59]. The use of traditional medicine practices in the 21
st
 century is 
fuelled by poverty, lack of pharmaceutical manufacturing capacity, and limited access to 
modern medicine [52,60,61]. Other factors like accessibility/availability, cultural influences, 
lack of effective treatments, and the use of phytomedicine for the relief of side effects caused 




by modern medicine (e.g. chemotherapy, antiretroviral drugs, and malaria treatments), also 
play a role [44,51,59].   
Scientific studies on the medicinal potential of plants are limited, with only 10-14% of all 
plant species being used for medicinal purposes [59,62]. However, some countries (such as 
Nigeria, China, India, and the USA), have made an effort to invest in phytomedical research, 
and have sparked a renewed interest in medicinal plants used in traditional medicine [62,63]. 
A paradigm shift is also occurring towards investigating whole plant extracts or 
phytomixtures, instead of focussing on single bioactive phytocompounds, which have, until 
recently, formed the majority of publications in the field of phytomedicine [54–56,63]. 
An article by Gwynn et al. [64], asks the very important question: “How can future 
opportunities be derived from traditional medicine?’ Although there are many hurdles ahead 
for the integration of phytomedicine into modern medicine, combining traditional knowledge 
and modern techniques, could perhaps be the answer to our challenges in modern medicine 
regarding decreases in effectiveness, drug resistance, toxicity, and combating complex 
diseases such as AIDS and cancer [14,62,64,65]. In an age of advance communication and 
technology, integrating the knowledge of medicinal plants obtained from traditional 
practitioners, may potentially help identify medicinal plants for investigation faster, which in 
turn may help reduce the selecting and screening process [62,64]. Some traditional 
practitioners also have extensive experience in combining different phytocompounds or herbs 
in order to enhance the desired medicinal effects (also referred to as synergism) or fight 
disease on multiple levels [42,62].    
 




2.3. The concept (theory and practice) of synergism 
The higher effectiveness of whole plant extracts and multi-compound combinations, in 
comparison to single plant derived active compounds, is thought to be due to the synergistic 
effects of the mixture of different bio-active and supporting constituents [56,66–68] The 
supporting compounds themselves could be pharmacologically inactive, but contribute to the 
stability, solubility and/or absorption rate of the active compounds [68–70]. In addition, the 
multi-target potential of medicinal plant extracts may also be due to the complex mixture of 
different bio-active and supporting phytocompounds [56,68].  
Among the first to define the concept of synergy, specifically pharmacological synergy, was 
Berenbaum in the 1980’s [71]. He developed the isobole method, which is considered to be 
one of the easier methods to test for synergism, since it is a demonstrative method that it is 
also independent of the mechanisms of action [68,71,72]. The dose of the two individual 
compounds being compared that gives half maximal response (EC50) is plotted separately on 
respectively the x and y axes of a graph. If the EC50 of combinations of the two compounds 
are plotted and connected on the graph and form a straight line, it will represent a combined 
or additive effect, meaning that there is no interaction between the two compounds, but that 
the combined effect is the sum of the two separate effects. If, however, there is an interaction 
between the two compounds, the “iso-effect” curve will be observed (Figure 2.3). Synergism 
is represented by a concave curve, with the combined effect of the two compounds being 
greater than the sum of the two separate effects. Antagonism is represented by a convex curve 
and the effect of the combination is less than the sum of the two compounds. 





Figure 2.3: Isoboles for antagonism, synergism and zero-interaction as obtained from Wagner et 
al., [73]. 
A different and less labour intensive approach to Berenbaums’ isobole method would be 
using fixed ratio combinations. In a study done by Tallarida et al. [74], investigating 
synergism between cocaine and buprenorphine, two fixed-ratio combinations (1:1 and 1:3) 
were used to test for synergy. Similar to the isobole method, the EC50 concentrations of the 
two individual drugs being compared were plotted separately on the x and y axes of the graph 
and a line drawn though the two points. This line represents the theoretically additive 
combination doses.  The additive EC50 values (zadd) are calculated from the individual drug 
EC50 concentrations according to the fixed-ratio combination used and plotted on the straight 
line, as can be observed in Figure 2.4 as point A (ratio of 1:1) and B (ratio of 1:3). Equation 1 
and 2 (below) are used to calculate the additive values (zadd) and standard error (SE) for the 
1:3 ratio. These equations may just be adjusted to apply to any ratio. The two drugs were then 
combined according to the fixed-ratios and the EC50 values of the combinations were 
determined. The individual drug concentrations in the combinations, at the EC50 value, were 
then plotted on the graph as seen in Figure 2.4 at point C (ratio of 1:1) and D (ratio of 1:3). 
The effect of the combined drug concentrations were less than the expected additive 




concentrations, and therefore represent a synergistic effect. To determine synergism, it is 
therefore not necessary to determine multiple drug combination EC50s to draw the curve as 
seen in Figure 2.3, [74]. 
zadd = (0.25 × 10) + (0.75 × 0.0175) = 2.51       [1] 
SE (zadd) = (0.25 × 1.14)2 + (0.75 × 0.00438)2 =0.285     [2] 
 
Figure 2.4: Isobologram showing synergism for the two fixed ratio mixtures of cocaine: 
buprenorphine as demonstrated in Tallarida et al, [74]. The EC50 of cocaine is 10 mg/kg (plotted 
on x-axis) and the EC50 of burprenorephine is 0.0175 mg/kg (plotted on y-axis). At point A, the drug 
ratio is 1:1 (5 mg/kg of cocaine:  0.00875 mg/kg of burprenorephine) and at point B the drug ratio is 
1:3 (2.5 mg/kg of cocaine: 0.013125 mg/kg of burprenorephine). Point C and D represent the 
synergistic effect of the combined drugs as a ratio of 1:1 and 1:3, respectively. See text for further 
details. 
Some of the advantages of synergy in phytotherapy or drug development include the multi-
target effect, due to the presence of various active and supporting compounds, which in turn, 
also inhibits drug resistance [55,56,69,73,75,76].  Subsequently, a decrease in toxicity and 
fewer side effects are also reported, since lower concentrations are needed to exert an effect 
[56,69,73,75]. The focus of some drug combination studies are not only to inhibit the 
mechanisms contributing to a specific disease, but also to activate protective and repair 
mechanisms to promote self-healing and prevent recurrence of the specific disease [54,76]. In 




a review article by Wagner et al. [73], the authors provide various examples of successful 
phytopharmaceutical drug combinations, including Iberogast
®
 which is comprised of nine 
plant extracts and is able to combat functional dysplasia and motility-related intestinal 
disorders on multiple levels,  the effectiveness of Hypericum compounds (Hypericin together 
with Epicatechin, Procyanidin, Hyperosid and/or Rutin) as an antidepressant compared to  
synthetic psychopharmacological drugs such as Imipramin, Flumazenil, Fluoxetin and 
Amitriptylin, and the efficacy of combination of the antimicrobial Amphotericin B  together 
with a grape seed extract (Vitis vinifera) to double the survival rate of Candida albicans-
infected mice compare a to Amphotericin B alone. 
Within the scope of the current study, combinations of different phytoestrogens, at 
concentrations that may be reached physiologically, have previously been shown to enhance 
anticancer effects by exerting their effects through many different molecular mechanisms 
[69]. For example, Kumar et al. [30] investigated the synergistic effects of three 
phytoestrogens (genistein, quercetin and biochanin A) and found that these phytoestrogens in 
a select combination (1:1:1 at 8.33µM each) had a more potent inhibitory effect on androgen-
responsive prostate cancer cell growth in vitro that the higher concentration (25µM) of the 
individual phytoestrogens on their own. 
2.4. Cyclopia (Honeybush) 
The genus Cyclopia (family: Fabaceae, tribe: Podalyrieae), more commonly known as 
honeybush due to its sweet honey-scented aroma, forms part of the indigenous South African 
fynbos biome and is predominantly found in the Eastern and Western Cape provinces (Figure 
2.2) [77–80].  There are approximately 24 species of Cyclopia in the wild of which a few are 
commercially cultivated as herbal tea including, but not limited to, ‘kustee’ (C. genistoides), 
‘vleitee’ (C. subternata & C. maculata), ‘bergtee’ (C. intermedia), and ‘Heidelbergtee’ (C. 




sessiliflora) [77,78,81–86]. This woody leguminous scrub consists of small trifoliate leaves, 
with the leaf shape and size differing between species, and distinctive bright yellow flowers 
(Figure 2.5) [78,80,81]. The stem, leaves and flowers of the plant are harvested for the 
manufacture of fermented
†
 and unfermented (green) honeybush tea [78,81,83,84,86,87]. 
Apart from its sweet aroma and taste, honeybush tea is also low in tannins and contains no 
caffeine, contributing to its increased popularity as a healthy beverage [77,78,83,88].  
 
Figure 2.2: Distribution of some Cyclopia species in Western and Eastern Cape region [89]. 
The use of Cyclopia, together with Aspalathus linearis (rooibos) and Agathosma betulina 
(buchu) by humans has a long history, and anecdotal evidence suggest that these indigenous 
South African plants were used by native inhabitants, such as the Khoi-San, as traditional 
medicinal teas to treat various ailments including digestive disorders (loss of appetite, nausea, 
spastic colon, colic), respiratory infections and disorders (asthma, chronic catarrh, pulmonary 
tuberculosis), and to help ease arthritis pain, and stimulate milk production in lactating 
women [77,80,85,90–92]. Gradually, the medicinal role of Cyclopia became less important 
while interest in the agriculture and agro-processing industry grew [80,93]. The honeybush 
industry is still young and in its developmental stage, but it has established itself in the herbal 
                                                 
†
 Fermentation of tea entails temperature-controlled oxidation of the plant material to enhance flavour and 
contribute to the renowned golden brown colour of classical tea [78,81,169]. 




tea market [77,80]. Currently, 100-175 tons of Cyclopia is exported annually, mainly to the 
United States and Europe (the United Kingdom, Germany, the Netherlands and Poland) 
[86,94,95].  
 
Figure 2.5: The leaves and flowers of different Cyclopia species. (A) Cyclopia subternata leaves, 
(B) Cyclopia subternata flowers, (C) Cyclopia intermedia leaves, (D) Cyclopia maculata leaves, (E) 
Cyclopia longifolia leaves, (F) Cyclopia genistoides  leaves, (G) Cyclopia genistoidses flowers, (H) 
Cyclopia sessilifora  leaves and (I) Cyclopia sessilifora   flowers [89]. 
A global shift in health-conscious lifestyle and food choices have resulted in a renewed 
interest in the potential health benefits and medicinal properties of Cyclopia [77,90,96,97]. 
The 2015 Nielsen Global Health and Wellness survey showed that 88% of consumers 
worldwide (Latin America (94%), Asia-Pacific (93%), Africa/Middle East (92%), Europe 
(79%) and North America (80%)) say they are willing to pay more for food that have proven 
health attributes [98]. This health-conscious trend, together with growing scientific research 
regarding health benefits of herbal teas, could create a possible new market for Cyclopia as a 
source of nutraceutical and potential pharmaceutical phytocompounds, especially since this 
indigenous plant has shown a vast variety of health promoting and disease fighting properties 
including, but not limited to, antioxidant, anti-inflammatory, -diabetic and -mutagenic 
properties as well as chemo-preventive or anti-cancer activity [28,77,78,93,99–105]. 
A B C D E 
F G H I 




2.4.1. Health benefits of Cyclopia 
The bioactivity of the Cyclopia species has been investigated and demonstrated in various 
research papers, and Cyclopia extracts have shown promising results in in vitro, in vivo and 
ex vivo studies.  
One of Cyclopia’s most prominent beneficial traits is its proven antioxidant activity. In a 
study by Dube et al. [106], the antioxidant capacity of different Cyclopia extracts were 
investigated using three methods: Oxygen Radical Absorbance Capacity (ORAC) assay, 
Trolox Equivalent Antioxidant Capacity (TEAC) assay and Ferric Reducing Ability of 
Plasma (FRAP) assay, and all the Cyclopia extracts, to some extent, displayed antioxidant 
behaviour by either scavenging free radicals, intercepting oxidation of oxidizable molecules, 
or preventing formation of reactive oxygen species (ROS). Similar antioxidant results were 
found in various other studies where different Cyclopia extracts and related phenolic 
compounds were able to inhibit Fe
2+
-induced microsomal lipid peroxidation, capture free 
2,2′-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS•+) radicals, and decrease 
oxidised glutathione (GSSG) in rat livers, thereby increasing the GSH/GSSG ratio, thus 
resulting in more effective cell resistance against oxidative stress [84,93,94,99,107].  
Cyclopia’s antioxidant properties go hand in hand with its anti-mutagenic and anti-cancer 
activity, since oxidative stress and free radicals have been linked to DNA damage and cancer 
progression [108]. Therefore, it is no surprise that Cyclopia extracts also displayed protective 
activity against the pro-carcinogens, aflatoxin B1 and 2-acetylaminofluorene (2-AAF), in the 
Salmonella mutagenicity assay, inhibited chemically induced skin tumour formation in ICR 
(Institute of Cancer Research) mice, and reduced azoxymethane (AOM) induced cell 
proliferation in the colonic mucosa of rats  [93,99,107,109,110].  




In addition to Cyclopia’s antioxidant, anti-mutagenic and anti-cancer activity, this indigenous 
plant also displayed anti-diabetic activity [78,107,111,112]. In a study by Muller et al. [111], 
Cyclopia intermedia extracts effectively reduced plasma glucose levels in Streptozotocin 
(STZ)-induced diabetic rats, as well as normalizing blood glucose levels and reducing plasma 
cholesterol levels in hyperglycaemic, high fat diet-induced OBIR rats.  
Another key characteristic of this multi-faceted plant, which forms the basis of the current 
study and the focus of our research group, is Cyclopia’s phytoestrogenic activity. Verhoog et 
al. [113–115], was one of the first to describe the phytoestrogenic activity of different 
Cyclopia  species (C. intermedia, C. sessiliflora, C. genistoides and C. subternata), followed 
by Mfenyana et al. [116,117], Visser et al. [102,105,118], and Mortimer et al. [28,119], who 
showed estrogen receptor (ER) subtype selectivity of Cyclopia fractions and related 
phytocompounds,  inhibition of E2-induced breast cancer cell proliferation in vitro, delayed 
ERα induced uterine growth in an immature rat uterotrophic model, and reduced tumour 
formation in a N-Methyl-N-nitrosourea (MNU)-induced rat mammary gland carcinogenesis 
model (as discussed in Chapter 1).   
To fully understand the importance of phytoestrogens, the next section will cover the 
mechanism of actions of phytoestrogens, as well as give a brief overview of the estrogen 
receptor signalling pathway. 




2.5.  Mechanisms of action of phytoestrogens 
Phytoestrogens are plant derived non-steroidal compounds with structural similarity to 17-β 
estradiol (Figure 2.5.1), and therefore can cause estrogenic, anti-estrogenic or selective 
estrogen receptor modulator (SERM)-like effects in animals and humans [120–122]. They are 
also referred to as dietary estrogens, since they are present in a variety of fruits, vegetables, 
grains, and seeds [121,123]. There are different classes of phytoestrogens including 
isoflavones (legumes and soybean products), coumestans (bean sprouts and fodder crops), 
stilbenoids (fruits such as grapes) and lignans (whole grains, fruits such as berries, pears and 
apples, and sunflower seeds)  [121,124–127]. 
 
Figure 2.5. Chemical structure similarity between the different classes of phytoestrogens 
(isoflavones, coumertans, stilbenoids, and lignans) and the endogenous female estrogen (17-β-
estradiol). Figure obtained from Moreira et al. [127]. 
 
 




The health potential of phytoestrogen-rich food is supported by epidemiology, in vitro and in 
vivo studies [120]. The occurrence of, for example, breast cancer in Asian and Eastern 
European countries, which predominantly consume a plant-based diet high in phytoestrogens, 
is lower than in Western countries, which consumes a diet high in animal based products 
[120,126,128]. Specifically, some of the phytoestrogens in soy, like genistein, have in various 
studies displayed anti-proliferative activity in both ER negative breast cancer cell lines (MDA 
231 and MDA 435) and in ER positive MCF-7 cells [120,129].   
Due to the favourable outcome of several studies, phytoestrogens are considered to be a safer 
and more natural alternative to synthetic estrogens used in HRT, with the same benefits as 
HRT (relief of menopausal symptoms, prevention of cardiovascular disease and osteoporosis) 
but with a lower risk of developing estrogen related cancers [120,126,130]. These potentially 
beneficial effects of phytoestrogens have resulted in a global increase in the consumption of 
phytoestrogen rich food and products [126]. However, the risks or side effects of 
phytoestrogens have not yet been clearly established. A review article by Patisaul et al. [131], 
describing the pros and cons of phytoestrogens, reveals the two-faced characteristic of some 
phytoestrogens. Genistein is an excellent examples of this, since this phytocompound has 
shown a biphasic response with agonist, instead of antagonist, effects at low concentrations 
and consequently, causing, rather than preventing, proliferation of cancer cells 
[124,129,132,133]. This example emphasizes the importance of fully understanding how 
phytocompounds exert their effects [124,132,133].   
The main structural feature of phytoestrogens are their phenolic rings together with hydroxyl 
groups, which is a prerequisite for compounds to bind to the ERs [126,127,134]. 
Phytoestrogens are, therefore, able to mimic endogenous estrogens and mediate their effects 
though the same estrogen signalling pathway [120]. Apart from the ability of phytoestrogens 
to bind to the ERs, they can also activate other receptors, including serotoninergic-, IGF-1-, 




aryl hydrocarbon-, and peroxisome proliferator-activated receptors, act like antioxidants by 
binding to free radicals, and affect signalling pathways important for cell survival and 
apoptosis including, but not limited to, tyrosine kinase, cAMP/protein kinase A, and MAP 
(ERK1,2, p38) kinase pathways [30,123,135]. The multifaceted characteristics of 
phytocompounds make them alluring candidates for cancer therapy development. For the 
purpose of the current study, however, we focus specifically on the estrogen signalling 
pathway. 
2.5.1.  Estrogen signalling pathway    
The biological effects of estrogenic molecules are mediated through two intracellular 
receptors, ERα and ERβ [136–138]. These receptors are ligand-dependent transcriptional 
factors which are expressed in specific target tissues (Figure 2.6) [136–139].  The structural 
(A to F region) and functional (DNA binding, ligand binding, activation demains: AF-1 and 
AF-2) domains between ERα and ERβ differ (Figure 2.7), which results in these subtypes 
having different physiological functions [136,140–143]. In terms of breast cancer, ERα is 
known to induce cell proliferation, whereas ERβ has shown anti-proliferative activity by 
antagonising ERα, thus creating a balance between opposite forces (as described by Heldring 
et al.) [137,143–146]. 





Figure 2.6: Distribution of ERα and ERβ in the human body, as demonstrated by Gustafsson 
[139].  
 
Figure 2.7: The structure representation of human ERα (top) and ERβ (bottom). Number 1 
(left) is the N-terminal, the numbers above the receptor illustration indicates the number of 
amino acids, and the numbers within the receptor illustration (ERβ) indicates the % homology 
between the respective domains of the two ERs [139]. 
There are four main ER signalling pathways including the (1) classical ligand-dependent, (2) 
ligand-independent, (3) estrogen response element (ERE)-independent, and (4) nongenomic 
(cell-surface signalling) pathways (Figure 2.8) [138]. When estrogenic molecules reach their 
target cells, they diffuse across the cellular membrane and bind to the ER in the cytoplasm, 
forming a ligand-ER complex, thereby activating and causing a conformational change of the 
ER  [136–138]. Pathway 1, 3 and 4 are ligand-dependent, and will be discussed first. 




Pathway 1: In the classical ligand-dependent pathway, the ligand-ER complex binds to the 
EREs in the promoter region of target genes, regulating the transcription of these genes  
[136–138,147].  
Pathway 3: The ERE-independent, also referred to as the tethered ligand dependent pathway, 
involves indirect binding of the ligand-ER complex to the promoter region of genes that do 
not contain EREs, by tethering to other transcription factors, such as Fos/Jun, and thereby 
influencing the regulation of these gene  [136–138,147].  
Pathway 4: In the non-genomic pathway, the estrogenic molecule binds to a membrane-
bound ER, activating enzymes, such as phosphatases and kinases. These affect membrane 
permeability, which this in turn results in rapid physiological changes  [136–138,148].  
Pathway 2: In contracts to the other signalling pathways, which are all ligand dependent, the 
ligand-independent pathway involves the phosphorylation of the ER by kinases, activating 
the ER via other signalling pathways (e.g. growth factor signalling) [136–138,148,149]. 
 
Figure 2.8: The four main ER signalling pathways including the (1) classical ligand-dependent, 
(2) ligand independent, (3) estrogen response element (ERE)-independent, and (4) nongenomic 
(cell-surface) signalling pathways, as obtained from Hall et al. [138]. 




2.6. Major phenolic compounds in Cyclopia SM6Met fraction 
As discussed in Chapter 1, the current study is built on the foundation of the findings from 
Verhoog et al. [113–115], Mfenyana et al. [116,117], Visser et al. [102,105,118] and  
Mortimers et al. [28,119]. Cyclopia, specifically the SM6Met extract and F3 fraction, like 
most other plants, consists of a variety of phytocompounds, of which the major phenolic 
compounds quantified are shown in (Table 1). However, the current study only focusses on 
the 7 major phenolic compound identified and quantified in the ER beta agonist fraction (F3), 
of SM6Met. The phenolic compounds used in the current study were, however, purchased, 
and not isolated from Cyclopia. 
Table 1: Major phenolic compounds quantified in the Cyclopia SM6Met extract [28,119]. 
Polyphenols Compound class SM6Met F3 
Mangiferin Xanthone 1.899 11.565 
Isomangiferin Xanthone 0.645 4.016 
p-Coumaric acid Hydroxycinnamic acid co-elution
b 
0.570 
Luteolin-7-O-rutinoside (scolymoside) Flavone 1.289 7.669 
Luteolin Flavone 0.040 0.205 
Protocatechuic acid Hydroxybenzoic acid 0.113 0.647 
Iriflophenone-glc Benzophenone 0.669 0.092 
Aspalathin-glc Flavone 0.700 nd
c 
Eriodictyol-7-O-rutinoside (eriocitrin) Flavanone 0.846 nd
c 
Phloretin-diglc Dihydrochalcone 1.278 nd
c 
Hesperetin-7-O-rutinoside (hesperidin) Flavanone 2.049 nd
c 
a
 Gram polyphenols per 100 gram dried plant extract 
b
 p-Coumaric acid co-elutes with aspalathin-glc where present; this means that the concentration cannot be 
determined accurately 
c 
Not detected  
It has been shown in literature that all 7 major phenolic compounds in F3 possess potential 
pharmaceutical characteristics including, but not limited to, antioxidant, anticancer, 
antibacterial and/or antidiabetic activity [100,150–160]. Of these 7 compounds, only 2 




(luteolin and mangiferin) have phytoestrogenic activity [158,161–163]. Even so, the 
contribution of the other 5 compounds should not be dismissed, since, as discussed 
previously, the inactive (non-estrogenic) compounds might support the active (estrogenic) 
compounds by contributing to the stability, solubility and/or absorption rate of the active 
compounds [68–70]. 
2.7. Conclusion 
It is apparent from reviewing the current literature that medicinal plant and related 
phytocompounds, have provided us with an endless source of inspiration, information and 
opportunities [8,50,164–166].  The title from an article by Pandey et al. [8]: ” Phytomedicine: 
An ancient approach turning into future potential source of therapeutics”,  perfectly describes 
the historical transition of phytomedicine, since even though medicine has evolved 
dramatically over the decades with the introduction and development of evidence-based 
science and related techniques, traditional medicine and medicinal plants still remain a vital 
source of treatment in same parts of the world and may herald the new pharmaceuticals of the 
21
st
 century [44,50,51,57–59]. 
Cyclopia, an indigenous South Africa plant used in the past as traditional medicine by the 
Khoi-San, has regained popularity in the phytomedical and nutraceutical industry, due to its 
multifaceted medicinal properties. Cyclopia extracts have shown promising properties in in 
vitro, in vivo and ex vivo studies, which includes phytoestrogenic, antioxidant, anti-diabetic, 
anti-inflammatory and anti-mutagenic activity [86,93,100,103–105,115]. It is apparent from 
these findings, that Cyclopia mediates it desired effects via multi-target mechanisms, 
potentially due to the complex composition of different phytocompounds in the plant. It has 
recently been shown in our research group that the ERβ-specific activity of SM6Met cannot 
be attributed to any of the individual major phenolic compounds identified and quantified in 




F3, and therefore the current study aims to investigate the possible combinatorial effects of 
these compounds [28].    
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Chapter 3: Material and Methods 
  




3.1 Characterisation of cell lines used in study 
In this study, three different cell lines were used based on specific characteristics.  Human 
embryonic kidney (HEK293) cells and African green monkey kidney fibroblast (COS-1) cells 
do not contain any endogenous estrogen receptors (ERs) and were used to investigate ER 
subtype specific activity, whereas MCF-7 BUS cells are an ER positive human breast cancer 
cell line and contain both ERα and ERβ. Medium used for cell maintenance and experimental 
procedures were supplemented as indicated in Table 3.1.  
3.1.1 Cell culture  
Human embryonic kidney (HEK293) cells (a kind gift from R. Louw, Stellenbosch 
University, ATCC (USA) cat# CRL-1573, passage 33), human breast cancer (MCF-7 BUS) 
cells (a kind gift from A. Soto, Tufts University, Boston, Massachusetts, USA, passage 118) 
and African green monkey kidney fibroblast (COS-1) cells (ATCC, USA cat# CCL-70, 
passage 4) were maintained in T75 flasks (Bio-Smart Scientific, South Africa), in 
supplemented phenol-red DMEM (Table 3.1), in a humidified cell incubator (95% 
humidity, 5% CO2 at 37˚C). All the cells were tested for mycoplasma infections using 
Hoechst stain [1] and only mycoplasma free cells were used. 
 
 




Table 3.1: Types of Dulbecco’s Modified Eagle’s medium (DMEM) used for cell culture 













Type of medium 
High glucose (4.5 g/L) 
phenol-red DMEM 
a 
Low glucose (1 g/L) 
phenol-red free DMEM 
a 
Low glucose (1 g/L) 
phenol-red free DMEM 
a 
High glucose (3.2 g/L) 
phenol red DMEM 








   (contains 1.2 g/L) 
L-Glucose (3.5 g/L) 
a 
-   - 
Sodium pyruvate 
(0.11 g/L) 
a  (contains 0.11 g/L)
 
(contains 0.11 g/L) (contains 0.055 g/L) 
1% (v/v) antibiotic 
mixture 
c, d  -   
10% (v/v) Charcoal 
a
 
stripped fetal calf 
serum 
e 
- -  - 




 (not stripped) 
 
 - -  
Purpose of medium 
Maintaining cells 
Replating COS-1 & 
MCF7 cells 
Serum starving cells 







, South Africa 
b 
Gibco® by Life Technologies, USA 
c 
100IU/ml penicillin and 100µg/ml streptomycin
 
d
 Invitrogen, South Africa 
e 
Merck, South Africa 
 
 




3.1.2 Western blot analysis 
Western blot analysis was conducted to characterise cell lines (HEK293 and MCF-7) used in 
this study in terms of ER subtypes. Un-transfected COS-1/HEK293 cells were used as 
negative control and COS-1/HEK293 cells transfected with the ER subtypes respectively, 
were used as positive controls. The presence/absence of ERα/β was identified with specific 
primary and secondary antibodies from Santa Cruz Biotechnology, Inc. and from Abcam, 
England (as indicated in results figure legends) at appropriate concentrations (Table 3.2).  
Table 3.2: Antibodies used in Western blot analysis. 
Protein Size Primary antibody Dilution Secondary antibody Dilution 
ERα  
(66kDa) 
ERα (MC-20): sc-542 
rabbit polyclonal antibody 
1:500 
goat anti-rabbit IgG - HRP  
sc-2030 
1:1000 
ERα (E115): ab32063 




ERβ (H-150): sc-8974 
rabbit polyclonal antibody 
1:1000 
goat anti-rabbit IgG - HRP  
sc-2030 
1:1000 
ERβ (EPR3777): ab92306 




GAPDH (0411): sc-47724 
mouse monoclonal antibody 
1:1000 
goat anti-mouse IgG - HRP  
Sc-2005 
1:5000 
 Transfection of cells 3.1.2.1
HEK293 and COS-1 cells, transfected with either ERα or ERβ, where used as positive control 
to investigate the presence or absence of the ERs in cell lines used in this study. 




per sterile 10cm cell binding plate 
(Corning
®
, USA) in supplemented DMEM: HamF-12 (1:1) medium (Table 3.1) and COS-1 
cells were seeded at a cell density of 1.5 x 10
6
 cells per sterile 10 cm plate in supplemented 




phenol-red DMEM. After 24 hours, the medium was changed to supplemented phenol-red 
free DMEM (Table 3.1) and the cells were transfected with 150ng of either ERα (pSG5-
hERα) or ERβ (pSG5-hERβ) expression vectors (see section 3.2.4.1) using FugeneXtreme 
Transfection Reagent (Roche®, South Africa) according to manufacturer’s specifications 
(3µl FugeneXtreme:µg DNA). The next day the cells were re-plated at a cell density of 2.5 x 
10
5
 cells per well in a sterile 6 well plate in supplemented phenol-red free DMEM and 
again allowed to settle overnight. 
 Preparations for Western blot analyses  3.1.2.2
The following day the transfected cells were rinsed with 2ml ice cold PBS/well and lysed 
with 150µl lysis buffer A (10 mM KCl, 0.1% NP-40, 10 mM, Hepes pH 7.5, 1.5 mM MgCl2) 
and Complete Mini protease inhibitor cocktail (Roche
®
, South Africa)) was added. Plates 
were shaken on ice for 15 - 20 minutes and frozen overnight at -20°C to ensure complete cell 
lysis. The cells were then thawed and scraped loose from the plate using a cell scraper after 
which the lysates were transferred to a 1.5ml tube. Cell lysates were centrifuged at 12 000 x g 
for 10 minute at 4°C and the clear lysates were then transferred to a new 1.5ml tube and 
stored at -20°C.  
Untransfected MCF-7, HEK293 and COS-1 cells were seeded at a cell density of 2.5 x 10
5 
cells per sterile 6 well plates. After 24 hours, the medium was changed to supplemented 
phenol-red free DMEM and after 48 hours the cells were lysed as described above.  
 Western blot 3.1.2.3
The cleared cell lysates (15µl) were separated with sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE), using a 10% SDS-PAGE gel (70V for 15 minutes and 




100V for 90 minutes using a BIO-RAD PowerPac™ HC and BIO-RAD Model Mini 
Protean®),  and transferred to a Hybond-ECL nitrocellulose membrane using an ECL Semi-
dry Blotter (Amersham Biosciences, USA) at 0.18A for 90 minutes. The membrane was then 
incubated in 10% (w/v) fat free milk powder (ERβ and GAPDH) or 5% (w/v) casein powder 
(ERα) dissolved in Tris-buffered saline (TBS) for 120 minutes on an orbital shaker. 
Thereafter the membrane was rinsed once with TBST (tris-buffered saline and 0.1% (v/v) 
Tween20), the specific primary antibody (see Table 3.2) was added to the membrane and 
incubated overnight at 4°C on an orbital shaker. Following incubation the membrane was 
washed with TBST (once for 20 minutes and twice for 5 minutes) after which the specific 
secondary antibody (which contains horseradish peroxidase [2]), see Table 3.2, was added 
and incubated at room temperature for 120 minutes on an orbital shaker. Thereafter, the 
membranes were washed again with TBST (same as before) and once with TBS after which 
the membrane was incubated with a chemiluminescent substrate (Clarity 
TM
 Western ECL 
Substrate from BIO-RAD) for 5 minutes and visualized either on medical x-ray film (Axim) 
or using the MyECL Imager (Thermo Fisher Scientific, Inc.), as indicated in results figure 
legends. The developed x-ray film was scanned in and the image adjusted in Microsoft Word 
2010, whereas the images from MyECL Imager was analysed and adjusted on MyECL 
Imager software version 2.0. A colour protein ladder (Color Protein Standard Broad Range 
ladder, Biolabs New England) was used to determine protein sizes. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as a protein loading control to evaluate the 








3.2 Assays to test estrogenic activity 
3.2.1 Test compounds  
17β-Estradiol (E2) and fulvestrant (ICI 182,780), obtained from Sigma-Aldrich
®
, were used 
as ER agonist and antagonist standards, respectively. Cyclopia extracts and fractions used in 
this study, previously prepared by Mortimer et al. [3], include the Cyclopia subternata 
(harvesting M6) sequential methanol (SM6Met) extract, the non-polar fraction (NP) of 
SM6Met and fraction 3 (F3) of the NP fraction. Cyclopia extracts and fractions were stored in 
a vacuum-sealed desiccator at room temperature in the dark, so as to prevent/decrease 
oxidation of samples [4–7]. Phenolic compounds investigated include: mangiferin, luteolin, 
luteolin 7-rutinoside (scolymoside), and iriflophenone-3-C-glucoside all from Sigma-
Aldrich
®
 (South Africa), protocatechuic acid and p-coumaric acid from Fluka™ Analytical, 
Sigma-Aldrich
®
, and isomangiferin from Chemos GmbH
®
 (Germany). Phenolic compounds 
were stored as recommended by manufacturers/suppliers.  
3.2.2 Preparation of compounds 
Stock solutions of compounds/extracts/fractions used in the study were prepared in one of 
three ways: (1) dissolved in dimethyl sulfoxide (DMSO), (2) dissolved in ethanol (EtOH), 
which was then evaporated or (3) dissolved directly in medium. Compounds prepared in 
DMSO were diluted 1000x in medium to achieve a 0.1% (v/v) DMSO concentration. Stock 
Solutions were stored at -20 ºC. 
17β-Estradiol (E2), fulvestrant (ICI 182,780), and the SM6Met extract, NP fraction and 
fraction 3 were prepared in DMSO from Sigma-Aldrich
®
 (South Africa). For re-constitution 
experiments, phenolic compounds, excluding mangiferin, were prepared in ethanol (EtOH). 




The EtOH was evaporated using nitrogen gas (Techne Sample Concentrator) in order to 
concentrate the compound mixtures at desired concentrations (Table 3.1), avoid oxidation of 
polyphenols and, in turn, also avoid the use of high levels of DMSO in tissue culture. 
Medium was added to the evaporated mixtures. Mangiferin did not dissolve in EtOH at high 
concentrations, but did dissolve in water and was consequently added directly to the medium 
at desired concentrations (as indicated in results figure legends). 
Table 3.1: Phenolic content in SM6Met F3 as identified in Mortimer et al. [3], which was used in 
reconstitution experiments. 










 1.1334 0.3936 0.0559 0.7515 0.0201 0.0634 0.0089 
1x M











































mg polyphenol in 9.8 mg SM6Met F3 
b 
molar concentration of polyphenols corresponding to 9.8mg/ml SM6Met F3  
3.2.3 Proliferation assay 
Methylthiszol Tetrazolium (MTT) [8] was used to investigate the proliferation activity of the 
test compounds/extracts/fractions in MCF-7 BUS cells (Figure 3.1). Live cells are able to 
reduce MTT to formazan, which can be measured with a spectrophotometer. Therefore, an 
increase in live cells signifies cell proliferation. The MTT assay was optimised from a 
previous lab protocol (see pre-optimisation protocol) to obtain optimal proliferation activity. 




M) mode was 
tested.  











Figure 3.1: Conversion of MTT to formazan via mitochondrial reductase in live cells. 
 Pre-optimisation protocol (previous lab protocol) 3.2.3.1
MCF-7 BUS cells (withdrawn from pen-strep for seven days), were seeded at a density of 1 x 
10
4
 cells per well in a sterile 96 well plate in supplemented phenol-red DMEM and allowed 
to settle overnight. The cells were then rinsed with 200µl/well pre-heated (37˚C) PBS after 
which they were steroid and serum starved with 200µl/well un-supplemented phenol red-
free DMEM (Table 3.1) for 24 hours. After starvation, the cells were treated with test 
compounds/extracts/fractions (as indicated in results figure legends) in supplemented 
phenol-red free DMEM for 24 hours (day 1), and re-induced after 48 (day 2) and 72 hours 
(day 3). Thereafter the MTT assay was performed. MTT powder (thiazolyl blue tetrazolium 
bromide from Sigma-Aldrich
®
) was dissolved in PBS (5 mg/ml) and filtered using a syringe 
and a cellulose acetate 0.2 µM 25mm syringe filter (Lasec, South Africa). After incubation 
with the compounds/extracts/fractions, cells were rinsed with sterile pre-heated (37˚C) PBS 
and subsequently incubated for 4 hours in MTT solution and un-supplemented phenol red 
free DMEM at a ratio of 1:4 (v/v). After the 4 hours, the medium containing the MTT 
solution was aspirated and 200µl/well DMSO was added to dissolve the formazan crystals 
and obtain a purple solution. Absorbance was measured at 550 nm on a spectrophotometer 
(BioTek
®
 Gen5TM). All results were expressed as fold relative to solvent (set at 1). 
 Optimisation 3.2.3.2
As dose response curves were required and optimal potency (EC50) and efficacy (fold 
induction) could not be obtained with the pre-optimization proliferation assay protocol, 




further optimisation was therefore needed. Optimization included changes in cell density, 
type of tissue culture plates and induction times (as indicated in results figure legends). 
Different cell densities were investigated in different size tissue culture plates: MCF-7 cells 
were seeded in sterile 96 well plates (1 x 10
4
 cells/well), 24 well plates (5 x 10
4
 cells/well) 
and 6 well plates (1 x 10
5
 and 2.5 x 10
5 
cells/well, respectively) in supplemented phenol red 
DMEM. Cells were also treated with a range of different concentrations of E2 (as indicated in 
results figure legends) to investigate optimal proliferative activity. In addition, induction time 
periods were optimised according to Karmaker et al. [9], which suggested an induction time 
period of 120 hours (5 days) with test compounds.  
 Post-optimisation protocol 3.2.3.3
Optimisation of the MTT assay revealed that Karmaker’s protocol provided the best cell 
proliferation results. Cell density, plate type and induction time period were changed 
accordingly. 
MCF-7 BUS cells were seeded at a cell density of 1 x 10
5
 cells per well in a sterile 6 well 
plate in supplemented phenol-red DMEM and allowed to settle overnight. The next day the 
cells were rinsed with 2ml/well pre-heated (37˚C) PBS and the medium was changed to 
2ml/well un-supplemented phenol red free DMEM. The cells were steroid and serum 
starved for 24 hours. After cell starvation (day 0), the cells were treated with test 
compounds/extracts/fractions (as indicated in results figure legends) prepared in 
supplemented phenol-red free DMEM for 72 hours (day 0 - 3), and re-induced for another 
48 hours (day 3 – 5). After inducing the cells with the compounds/extracts/fractions for a 
total of 120 hours (5 days), the MTT assay was conducted as described in the pre-
optimisation protocol. After 4 hours the medium containing the MTT solution was aspirated 
and 2ml of DMSO was added to each well and mixed until a clear purple solution was 




observed. The purple DMSO cell mixture was then re-plated into a 96 well plate and the 
absorbance measured at 550 nm with a spectrophotometer (BioTek
®
 Gen5TM). All results 
were expressed as fold relative to solvent (set at 1). 
3.2.4 Promoter Reporter Studies 
 Plasmids and plasmid preparation 3.2.4.1
The following plasmids were used in promoter reporter studies:  
 The estrogen receptor (ER) subtype expression vectors for human ERα (pSG5-hERα, 5860 
bp) and human ERβ (pSG5-hERβ, 5663 bp) were obtained from S. Denger and F. Gannon 
[10]. 
 Two estrogen response element (ERE) containing promoter reporter plasmids, one containing 
the ERE from the vitellogenin gene (ERE.vit2.TATA.luc, ±5730bp) was obtained from K. 
Karach [11] and the second containing the ERE from the human PS2 gene (pGL3-
2ERE.PS2.luc, ±5614bp) was obtained from B. Belandia [12]. Both plasmids contain a 
coding region for luciferase. 
 The pGL2 basic empty vector (5598 bp), obtained from Promega (USA), contains no 
eukaryotic promoter or enhancer sequences and was use as a filler plasmid. 
Glycerol stocks of transformed DH5α Escherichia coli cells (made competent using the 
calcium chloride method and transformed using the heat shock method [13]) containing the 
relevant plasmids, were grown overnight at 37 ͦ C in 200ml lysogeny broth (LB) medium 
(0.024 M NaCl, 5 g/L Yeast Extract (Merck, South Africa), and 10 g/L Tryptone (Merck, 
South Africa)) in the presence of 50 µg/ml ampicillin until the bacterial cells reached an 
optical density (O.D.600) of 2–4. 






 Plasmid Maxiprep System (Promega, USA) was used according to the 
manufacture’s specifications to isolate plasmid DNA. The concentration and purity of DNA 
was determined using the NanoDrop
®
 ND-100 spectrophotometer (Thermo Fisher Scientific 
Inc.). The DNA concentration was calculated by the NanoDrop
®
 2000 software from the 
absorbance determined at 260 nm, while the purity was calculated using the absorbance ratio 
of 260/280 nm, since pure DNA at this wavelength would give a ratio of ~1.8. Restriction 
enzyme digestion of the plasmid DNA was conducted using the restriction enzyme HindIII 
(5U/µg) obtained from Fermentas (Thermo Fisher Scientific Inc.) for all the plasmid 
constructs. The plasmid DNA (0.2µg DNA/well, digested and undigested) was separated 
using agarose gel electrophoresis (100V for 30 - 60 minutes) on a 1% agarose gel. Plasmid 
DNA size and integrity was subsequently analysed and evaluated using a GeneRuler™ 1kb 
DNA Ladder (Inqaba, South Africa) and E-Capt Vilber Lourmat Software version 12.9. 
 Promoter reporter assay 3.2.4.2
Promoter reporter assays [14] were used to evaluate ER subtype specific agonist and 
antagonist activity of the test compounds/extracts/fractions in HEK293 cells. These cells 
were transfected with either an ERα expression vector (pSG5-hERα) or an ERβ expression 
vector (pSG5-hERβ), as well as an ERE-containing promoter reporter plasmid 
(ERE.vit2.luc/ERE.PS2.luc) and a pGL2 basic empty vector. Fulvestrant (ICI), SM6Met, NP 
and F3 were tested in agonist (in the absence of E2) and antagonist (in the presence of E2 10
-
11
M) mode for both ER subtypes. Promoter reporter assays were also used to (1) conduct dose 
response analysis (3.2.4.2.1), to obtain potency (EC50) and efficacy (fold inductions) of E2 
and selected polyphenols (Table 3.1), as well as for (2) addition and subtraction studies 
(3.2.4.2.2) and (3) to investigate synergism (3.2.4.2.3). These three studies were only 
conducted in agonist mode (in the absence of E2) for both ER subtypes. 




HEK293 cells were seeded at a density of 4 x 10
6
 cells per sterile 10cm cell-binding plate 
(Corning
®
, USA) in supplemented DMEM:HamF-12 (1:1) medium, and allowed to settle 
overnight. The next day the plates were rinsed with pre-heated (37˚C) PBS and the medium 
was changed to supplemented phenol red free DMEM. Cells were then transfected with a 
total of 6150ng plasmid DNA (150ng ER, 1500ng ERE and 4500ng pGL2basic) per 10cm 
plate using FugeneXtreme Transfection Reagent (Roche
®
, South Africa) according to 
manufacturer’s specifications. 24 Hours after transfection, cells were re-plated at a cell 
density of 5 x 10
4 
cells per well in sterile 24 well binding plates (Corning
®
, USA).  The 
following day the cells were treated with selected test compounds/extracts/fractions (at 
concentrations as indicated in results figure legends) for another 24 hours. Thereafter, the 
cells were rinsed with 500µl/well ice cold PBS and lysed with 50µl/well passive lysis buffer 
(10% (v/v) glycerol, 0.2% (v/v) Triton, 2.8% (v/v) Tris-phosphate EDTA and 1.44 mM 
EDTA) after which the cell lysates were frozen overnight at -20˚C. Luciferase activity of cell 
lysates were measured in relative light units (RLU) using the luciferase assay system (Figure 
3.2) and a Veritas microplate luminometer. Luciferase assay reagent (beetle luciferin) 
[Promega, USA] was added to cell lysates at a ratio of 5:1. RLU values were normalised 
using protein concentrations of lysates (5µl) determined with the Bradford method [15], 




 spectrophotometer. This was done to ensure that 
any increase in luciferase activity was due to transactivation of the promoter reporter by the 
ligand activated receptor, and not due to plating error or an increase in cell number. Results 
were expressed as fold relative to solvent (set at 1). 






    Luciferase         
Light 
(RLU) 
+ ATP + O2  Oxyluciferin + AMP + PPi + CO2 + 
    Mg 
2+ 
        
Figure 3.2: Mechanism of luciferase activity 
3.2.4.2.1 Dose Response protocol 
Dose response promoter reporter analysis was conducted with increasing concentrations of 
test compounds (individually and in fixed-ratio combinations). The effects were plotted using 
a XY line graph in Graphpad where the logarithm of the increasing concentrations of the tests 
compounds are plotted on the X axis and the response in RLU/mg protein on the Y axis. Data 
was analysed using a nonlinear regression curve fit with log (agonist) vs. response (three 
parameters). From the dose response curve, the potency (EC50 values) and efficacy (fold 
induction) of the test compounds (individually and in fixed-ratio combinations) were 
obtained.  
3.2.4.2.2 Addition and Subtraction protocol 
F3 was reconstituted using the 7 major phenolic compounds identified in this F3 (Table 3.1) 
[3]. For the addition protocol, the concentrations of one of the seven compounds was 
individually increased to 10-fold (10x) or 100-fold (100x) the concentration in F3, 
respectively, whereas for the subtraction protocol, six of the seven phenolic compounds were 
prepared at 100-fold (100x) the concentration of these compounds in F3 with the 
concentration of only one compound per experiment decreased (subtracted) to the 
concentration in F3 (1x).  
 




3.2.4.2.3 Synergism protocol 
A well-known protocol to determine synergism is the isobologram method as demonstrated in 
Tallarida et al. [16]. In this protocol the EC50 values, obtained from dose response curves 
(3.2.4.2.1), of the individual compounds to be evaluated would be plotted on the y and x –
axes, respectively, with a line drawn between the two points. The EC50 values of the 
individual compounds would then be combined in a fixed ratio manner, were the combination 
is increased and decreased exponentially at the fixed ratio, to determine the EC50 of the 
combination. If the EC50 value of the combination fell upon this line, the effected is 
considered to be additive. Values below the line are considered to be synergistic, while those 
above the line are considered antagonistic. For a more detailed description of the isobologram 
method, see section 2.3 in the literature review. In this study, mangiferin and luteolin were 
chosen to be investigated for synergism. Since the EC50 of mangiferin could not be obtained, 
increasing concentrations of mangiferin was combined with the EC50 of luteolin. 
3.2.5 Whole cell binding  
COS-1 cells were seeded at a cell density of 1.5 x 10
6
 cells in supplemented phenol-red 
DMEM in sterile 10cm plates and allowed to settle overnight. The next day the medium was 
changed to supplemented phenol-red free DMEM and the cells were transfected with 
150ng of either ERα (pSG5-hERα) or ERβ (pSG5-hERβ) expression vectors (see section 
3.2.4.1) using FugeneXtreme Transfection Reagent according to manufacturer’s 
specifications (3µl FugeneXtreme:1µg DNA). After 24 hours, the cells were re-plated in 
supplemented phenol-red free DMEM at a cell density of 5 x 10
4
 cells per well in sterile 24 
well plates and again allowed to settle overnight. Thereafter the cells were rinsed three times 
with sterile pre-heated (37°C) PBS and incubated for 4 hours in un-supplemented phenol-
red free DMEM with 20 nM radio-labeled estradiol (81Ci/mmol 2,4,6,7-
3
H-17-β-etradiol 






) alone (total binding) or  in combination with 10
-5
M of 
unlabelled estradiol (non-specific binding) to evaluate specific binding of mangiferin and 
luteolin at 100x their concentration in F3 (Table 3.1). After 4 hours, the cells were placed on 
ice and rinsed (three times for 15 minutes, respectively) with ice cold 0.2% PBS-BSA 
(bovine serum albumin from Sigma-Aldrich
®
). Cells were lysed with 100µl/well passive lysis 
buffer (10% (v/v) glycerol, 0.2% (v/v) Triton, 2.8% (v/v) Tris-phosphate EDTA and 1.44 
mM EDTA) and shaken for 20 minutes at room temperature after which the cell lysates were 
frozen at -20˚C.  
Protein concentration of lysates (5µl) was determined using the Bradford method [15]. The 
remaining lysates were transferred to scintillation vials to which 1ml scintillation fluid per 
vial (Quickszint FLOW 2, Zinsser Analytic, South Africa) was added. Counts per minute 
(CPM) were determined using the Beckman LS3801 Beta-scintillation counter (Beckman
®
, 
South Africa) and results (CPM) were normalised to protein (mg/ml) values. Data was 
presented as specific binding which was determined by subtracting nonspecific binding from 
total binding (Specific Binding = Total Binding – Non-Specific Binding). 
3.3 LC-MS/MS analysis 
LC-MS/MS analyses were conducted at the Central Analytical Facilities (CAF) of 
Stellenbosch University on a Waters Acquity® ultra-performance liquid chromatography 
(UPLC) system connected to a Waters Synapt G2 quadrupole time-of-flight (QTOF) mass 
spectrometer (Milford, MA, USA). The UPLC system comprised a binary pump, an in-line 
degasser, column compartment and an Acquity photo diode array (PDA) detector. The mass 
spectrometer was equipped with an electrospray ionization (ESI) source and samples were 
ionized as described in Albrecht et al. [17]. A Waters UPLC BEH C18 column (2.1 × 50 mm, 




1.7 μm particle size) was used for separation and 1 μl of each sample was injected. The 
gradient program used was as indicated in Table 3.1. 





% Solvent A 
H2O (0.1% formic acid) 
% Solvent B 
Acetonitrile (0.1% formic acid) 
Initial 0.350 90.0 10.0 
0.20 0.350 90.0 10.0 
14.00 0.350 66.0 43.0 
15.00 0.350 40.0 60.0 
15.10 0.350 90.0 10.0 
17.00 0.350 90.0 10.0 
 
3.4 NMR analysis 
1
H NMR spectra were recorded at the NMR unit in the Central Analytical Facilities (CAF) of 
Stellenbosch University. The samples were dried under vacuum, dissolved in DMSO-d6 or 
pyridin-d5, respectively, and the proton spectra acquired on a 600MHz Agilent Unity Inova 
spectrometer utilizing an Inverse Detection Pulsed Field Gradient, 5mm probe and utilizing 
the default proton acquisition parameters of the VnmrJ 4.2 instrument software. The spectra 
were obtained at room temperature and the recorded data further processed and referenced 
against the residual DMSO signal set at 2.5ppm, using the Mestrenova 11 software package. 
Electrospray ionization mass spectrometry (ESI-MS) was used to ddetermine the accurate 
mass of the molecular ion (M+1) in the positive ionization mode, thereby further confirming 
each structure molecular weight and molecular formula. 
3.5 Statistical analysis 
The Graph Pad Prism
®
 v5.0.3.477 software was used to manipulate, graphically visualize and 
statistically analyse the data obtained from all assays. Bar graphs were statistically analysed 




using One-way ANOVA and Dunnett’s multiple comparison’s test as post-test. Dose 
response graphs were fitted using a nonlinear regression curve fit with log (agonist) vs. 
response (three parameters) to determine potency (EC50) and efficacy (fold induction). P-
values were represented as follow: P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***), as 
indicated in results figure legends. Average ± SEM is indicative of (n) independent 
experiments, as indicated in results figure legends. 
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Chapter 4: Optimisation and Validation of 
Experimental Systems  




Recently, the concept of combinatorial or synergistic drug interactions has received 
considerable attention due to the discovery and understanding of novel phytoestrogenic 
nutraceuticals for both the treatment of menopausal symptoms as well as the prevention of 
estrogen-induced breast cancer [1–3]. Due to the increased risk of developing breast cancer 
associated with hormone replacement therapy, women are seeking alternatives such as plant 
extracts containing high levels of phytoestrogens, that have been shown to alleviate 
menopausal symptoms with possible fewer side effects and risks [1,4–6]. However, more 
research is required to fully understand how the phytoestrogens in complex plant extracts 
interact to exert their favourable combinatorial or synergistic effects.  
Currently, the most common method to investigate drug interactions and to determine 
possible synergism is the isobole method [3,7–10]. This method requires establishing the 
potencies of the individual drugs involved, as well as the potencies of fixed drug 
combinations. To achieve accurate drug potencies, various factors need to be considered 
since optimal and accurate results are not only dependent on the concentration and effect of 
the drug, but also on the sensitivity of the experimental system (cell type, target e.g. receptors 
or response elements, and assay) [11–14].  
The current project investigates F3, one of the fractions of the phytoestrogenic nutraceutical, 
SM6Met [15]. Specifically, as the current project aims to evaluate the interaction and 
possible synergistic contribution of the 7 individual major phenolic compounds identified in 
F3 to the favourable estrogenic profile of this fraction, optimisation of the experimental 
model was required. For this reason, the cell lines used in the experimental model were 
characterised and optimisation of the experimental protocols were investigated to increase 
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sensitivity. Following optimisation, the experimental protocol was validated using SM6Met 
and fractions thereof [15]. 
4.2. Results and Discussion 
4.2.1. Characterisation of cell lines  
The two cell lines used, human embryonic kidney cells (HEK293) and human breast cancer 
cells (MCF-7 BUS), were chosen based on specific characteristics needed to aid in 
investigating the estrogenicity of compounds/extracts/fractions. The HEK293 cells do not 
express any endogenous ERα or ERβ [16], and for this reason was used to investigate ER 
subtype specific activity through separate transfections with expression vectors for ERα and 
ERβ, respectively. Since this cell line is of human origin [17], it is thought to be a more 
physiologically relevant system for investigation of the expression of human ER. On the 
other hand, the MCF-7 BUS cells endogenously expresses both ERα and ERβ [18], and is 
therefore a physiologically relevant system for the investigation of the effect of the 
compounds/extracts/fractions on breast cancer cell proliferation.   
Western blot analysis was performed to validate the ER status of the HEK293 and MCF-7 
BUS cells. As expected, the HEK293 cells did not express any endogenous ERα or ERβ 
(Figure 4.1 A & B, lane 3), whereas the MCF-7 BUS cells expressed both ER subtypes 
(Figure 4.1 C & D, lane 4). Furthermore, it was observed that the intensity of the ERα 
(66kDa) protein band (Figure 4.1 C, lane 4) was more prominent than the intensity of the 
ERβ (56kDa) protein band (Figure 4.1 D, lane 4), suggesting higher expression of ERα than 
ERβ in the MCF-7 BUS cell line. However, since different antibodies were used for the ERα 
and β subtypes, albeit from the same company, affinity of the antibodies for the respected 
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epitopes should not be assumed to be identical. Nonetheless, literature has also shown higher 
expression of ERα in the MCF-7 breast cancer cell line [18]. 
 
Figure 4.1: Characterization of the human embryonic kidney (HEK293) and the human breast 
cancer (MCF-7 BUS) cell lines. A & B: Western blot analysis confirms the absence of the estrogen 
receptors subtypes (ERα and ERβ) in the HEK293 cell line. Un-transfected COS-1 cells, indicated as 
COS-1 (-), were used as negative control and COS-1 cells, transfected with either pSG5-hERα or 
pSG5-hERβ, indicated as COS-1 (+α) and COS-1 (+β), respectively, were used as positive controls. 
(A) ERα (MC-20):sc-542 was diluted 1:500  and (B) ERβ (H-150):sc-8974 was diluted 1:1000. 
Results were visualised on x-ray film. C & D: Western blot analysis confirms the presence of both 
estrogen receptor subtypes (ERα and ERβ) in the MCF-7 BUS cell line. Un-transfected  COS-1 cells, 
indicated as COS-1 (-), were used as negative control and HEK293 cells transfected with either pSG5-
hERα or pSG5-hERβ, indicated as HEK (+α) and HEK (+β), respectively, were used as positive 
controls. (C) ERα (ab75635) and (D) ERβ (ab3576) were both diluted 1:400. Results were visualised 
on a MyECL Imager. A, B, C & D: Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used 
as a protein loading control.  
From the Western blot results we may conclude that the HEK293 cells do not contain the ER 
subtypes and is therefore an ideal cell line to investigate and compare the transactivational 
activity of the phytoestrogenic extracts and fractions via the respective ER subtypes. In 
addition, this cell line is generally considered a good model for transactivation studies [19]. 
In contrast to the HEK293 cell line, the MCF-7 BUS cells endogenously expresses both ERα 
and ERβ, and are thus an ideal system for investigating the effects of the phytoestrogenic 
extracts and fractions in a physiological relevant cell environment.  
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4.2.2. Optimisations of assays used to test estrogenic activity 
Promoter reporter and cell proliferation assays were previously used to evaluate the 
favourable estrogenic profile of SM6Met. Specifically, previous studies demonstrated that 
SM6Met displayed ERα antagonism and ERβ agonism in both COS-1 and HEK293 cells, and 
inhibited estrogen induced MCF-7 BUS breast cancer cell proliferation [15,20]. Therefore, 
following from the SM6Met studies, the same assays were used to investigate a fraction (F3) 
of SM6Met, which displayed augmented ERβ agonist activity [15]. However, no estrogenic 
activity was observed with any of the individual major phenolic compounds in F3 [15], even 
though some of these compounds displayed estrogenic activity in other studies [21–23].  
To determine interaction and possible synergism of the phenolic compounds identified in 
SM6Met F3, a robust system, with high sensitivity, is required to detect small changes in the 
inflection point of a dose response curve. Consequently, the assays used in the current study, 
cell proliferation in MCF-7 BUS cells and promoter reporter assay in HEK293 cells, required 
optimisation to increase sensitivity, specifically by obtaining optimal efficacies (fold 
induction) and accurate potencies (EC50). Estradiol (E2), an endogenous ER ligand that binds 
to both ER subypes with high affinity [24] and promotes proliferation of breast cancer cell 
lines [25], was used as positive control for the optimisation of both assays. 
4.2.2.1. Optimisation of cell proliferation assay protocol: investigating different cell 
numbers, tissue culture plate sizes and various induction times 
The proliferation assay was optimised from a previous cell proliferation assay laboratory 
protocol [15], which entailed using 96 well plates with a cell density of 1 x 10
4
 cells/well. 
The MCF-7 BUS cells were induced with increasing concentrations of E2 for a total of 72 
hours (3 days), and produced an efficacy of only 1.54 ± 0.04 fold (Figure 4.2 A). An 
experimental system with a higher efficacy would ultimately be more sensitive to small drug 
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induced changes, and subsequently produce a more accurate potency. This increase in 
sensitivity is essential when investigating interaction and possible synergism of complex 
mixtures such as in SM6Met and its fractions. Therefore, a literature search for other 
protocols with increased sensitivity was conducted. One of the highest efficacies found 
during the literature search was in a study by Karmakar et al. [26], where the authors 
achieved a 5-fold induction with 10
-9 
M E2 using 6 well plates (1 x 10
5
 cells/well) and 
inducing for a total of 120 hours (5 days). Since the differences between the two protocols 
were: (1) total induction time, (2) tissue culture plate sizes and (3) cell number per surface 
area, these three conditions (Table 4.1) were investigated in order to achieve increased 
efficacy in our cell proliferation assay.  
























































Efficacy (fold induction) = 1.54  0.04 fold
Log EC50 = -11.43  0.20
Potency (EC50) = 3.71 x 10
-12 M
Efficacy (fold induction) = 3.67  0.08 fold***
Log EC50 = -11.27  0.07
ns
Potency (EC50) = 5.39 x 10
-12 M
Figure 4.2: Cell proliferation studies comparing potency (EC50) and efficacy (fold induction) of 
(A) a previously used laboratory protocol and (B) a new post-optimisation protocol. (A) MCF-7 
BUS cells were plated at a cell density of 1 x 10
4
 cell/well in 96 well plates and induced with 
increasing concentrations of E2 for a total of 3 days. (B) MCF-7 BUS cells were plated at a cell 
density of 1 x 10
5
 cell/well in a 6 well plate and induced with increasing concentrations of E2 for a 
total of 5 days. Curve fitting: nonlinear regression with log (agonist) vs. response (three parameters). 
Statistical analysis: unpaired t-test to compare efficacy and log EC50 of (A) a previously used 
laboratory protocol and (B) a new post-optimisation protocol,*P <0.05, **P< 0.001, ***P<0.0001 and 
ns
no significant difference. 
Cells were either induced for a total of 72 hours, from previous laboratory protocol (Figure 
4.3 A, C, E & G), or 120 hours, from the Karmakar protocol (Figure 4.3 B, D & F). Various 
cell densities were also investigated with different tissue culture plate sizes: 96 well plates 
with 1 x 10
4
 cells/well, from previous laboratory protocol (Figure 4.3 A & B), 24 well plates 
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with 5 x 10
4
 cells/well (Figure 4.3 C & D) and 6 well plates with either 1 x 10
5
 cells/well, 
from the Karmakar protocol  (Figure 4.3 E & F), or 2.5 x 10
5 
cells/well (Figure 4.3 G). 






M) was used as a positive control. Since 
10
-9
 M E2 was the point where the curve plateaued in Figure 4.2 A, 10
-9
 M E2 fold induction 
for the three conditions where summarised in Table 4.1.  
Table 4.1: Comparison of E2 (10
-9
 M) fold induction using different optimisation conditions 
(total induction time, plate size and cell density).  
 
Plate size Cells/well 
10
-9 
M E2 fold induction after 
72 hours (3 days) 
10
-9
M E2 fold induction after 
120 hours (5 days) 
 96 well 1 x 10
4
 1.07 ± 0.03 1.61 ± 0.02 ***
 
 24 well 5 x 10
4
 1.23 ± 0.02 
###
 1.45 ± 0.01 ***
,###
 
 6 well 1 x 10
5
 1.49 ± 0.10 
###
 3.06 ± 0.05 ***
,###
 
 6 well 2.5 x 10
5
 1.46 ± 0.03 
ns 
- 
 Statistical analysis: unpaired t-test, 72 hour (3 day) protocol vs 120 hour (5 day) protocol *P <0.05, **P< 










The results from Table 4.1 and Figure 4.3 suggest that the longer induction time period of 
120 hours (Figure 4.3 B, D & F) achieved significantly (P<0.0001) higher fold induction 
throughout compared to the short induction time period of 72 hours (Figure 4.3 A, C, E & G). 
Furthermore, the different plate sizes with their allocated cell densities were compared within 
each of the induction time periods (72 hours and 120 hours). Within the 72 hours protocol, 
there was a significant increase (P<0.0001) in fold induction associated with the increase in 
surface area of the cell culture plates (Figure 4.3 A, C & E). There was, however, no 
significant difference in fold induction between the different cell densities (1 x 10
5 
cells/well 
and 2.5 x 10
5 
cells/well) in the 6 well plates (Table 4.1). Within the 120 hour protocol, there 
was a significant (P<0.0001) decrease in fold induction between the 96 well and 24 well 
plates, and a significant (P<0.0001) increase in fold induction when comparing the 6 well 
plate to the 96 well and 24 well plates. The highest cell proliferation induction, 3.06 ± 0.05 
fold, was observed with the 6 well plates (1 x 10
5 
cells/well) using the longer induction time 
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period (Table 4.1; Figure 4.3 F). Accurate results for the 6 well plates (2.5 x 10
5 
cells/well) 
using the longer induction time period could not be obtained, since the cells were already 
100% confluent on day 3 and began to lift from the plate surface (results not shown in Figure 
4.3).  
Although the 3.06-fold induction of proliferation obtained from 10
-9 
M E2 (Figure 4.3 F) was 
lower than that of Karmakar et al. [26], it was a significant improvement compared to the 
efficacy (1.07-fold) achieved with the previous laboratory protocol (Figure 4.3 A) and the 
other optimisation conditions tested (Figure 4.3 B, C, D, E & G). Cell density, plate size and 
induction time period were thus changed accordingly and a dose response curve was 
produced for the post-optimised protocol to compare potency (EC50) and efficacy (fold 
induction) to that of the pre-optimised protocol (Figure 4.2). Although the potencies for the 





and 5.37 x 10
-12
 M, respectively), the efficacy obtained with the post-optimised protocol 
(Figure 4.2 B), was more than double and significantly different (P<0.0001) from the efficacy 
obtained with the pre-optimised protocol (Figure 4.2 A) at 3.67 ± 0.08 fold vs 1.54 ± 0.04 
fold, respectively. 
As optimisation of the cell proliferation assay revealed that the Karmakar protocol [26] 
provided a significant overall improvement in cell proliferation efficacy, compared to the 
previous protocol, cell density, plate size and total induction time was changed accordingly 
for the validation study (4.2.3.1). The post-optimised protocol produced an efficacy twice that 
of the pre-optimised protocol, resulting in a more sensitive system, which, as stated 
previously, is important when investigating drug interactions and possible synergism.    
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Figure 4.3: Optimisation of cell proliferation studies. Different cell densities, plate sizes and 







to determine optimal MCF-7 BUS cell proliferation conditions. A & B: 96 well plates (1 x 10
4
 
cells/well) with an induction time of 3 days (A) or 5 days (B). C & D: 24 well plates (5 x 10
4
 
cells/well) with an induction time of 3 days (C) or 5 days (D).  E & F: 6 well plates (1 x 10
5
 
cells/well) with an induction time of 3 days (E) or 5 days (F). G: 6 well plates (2.5 x 10
5
 cells/well) 
with an induction time of 3 days. Statistical analysis: One-way ANOVA with Dunnett’s Multiple 
Comparisons Test as  post-test, all columns compared to solvent control set to 1 (black bar),* P <0.05, 
** P< 0.001, *** P<0.0001. 
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4.2.2.2. Optimisation of Promotor Reporter Assay 
Previous studies in our group investigated the estrogenicity of Cyclopia extracts and phenolic 
compounds using promoter reporter assays in COS-1 cells, an African green monkey kidney 
cell line [20,27]. In addition, Mortimer et al. [16], focused on the optimisation of a promoter-
reporter assay for determining the estrogenicity of the SM6Met extract and phenolic 
compounds in HEK293 cells, a human embryonic kidney cell line. This cell line is thought to 
be a more physiologically relevant model for human related studies, since it is a human cell 
line whereas the COS-1 cell line is of monkey origin. Mortimer’s protocol entailed 
transfecting HEK293 cells with either hERα or hERβ, and an ERE.vit2.luc promoter reporter 
construct, which contained two ERE sequences obtained from the vitellogenin gene 
expressed in ovipare species [16,28,29]. Results obtained from Mortimer’s study 
demonstrated the ability of E2 (10
-9 
M) treatment to induce the promoter-reporter construct 
(ERE.vit2.luc) by 3.1-fold and 6.3-fold via ERα and ERβ, respectively [15,16].  
As mentioned before, a higher efficacy would ideally result in a more sensitive system to 
investigate drug interaction and determine possible synergism. Therefore, in the current 
study, a second ERE-containing promoter reporter construct (ERE.PS2.luc) was investigated. 
This ERE-containing reporter construct consists of an ERE sequence obtained from the 
human PS2 gene expressed in breast cancer cells [12][30], and previously demonstrated good 
transactivation activity via the ER subtypes (predominantly ERα), however, the results varied 
between different cell types [11–14,31]. For example, 10
-9
 M E2-induced transactivation of 
the PS2-ERE via ERα resulted in a 2-fold induction in Cho-K1 cells [11], an approximate 5-
fold induction in COS-1 cells [12], and around 12-fold induction in Hela cells [31].  Thus, in 
the current project, the E2-induced transactivation of ERE.vit2.luc and ERE.PS2.luc via ERα, 
as well as ERβ, was investigated and the obtained efficacies and potencies, specifically in the 
HEK293 cells, were compared.  
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The two EREs showed similar results for ERα (Figure 4.4 A & C), with no significant 
difference between the efficacies (6.02 ± 0.22 fold for ERE.vit2.luc and 6.22 ± 0.14 fold for 
ERE.PS2.luc) or potencies (8.14 x 10
-12
 M and 1.21 x 10
-11
 M for ERE.vit2.luc and 
ERE.PS2.luc, respectively). Moreover, ERβ (Figure 4.4 B & D) displayed a small but 
significant (P<0.05) difference between the potencies (8.04 x 10
-10
 M for ERE.vit2.luc and 
1.62 x 10
-10
 M for ERE.PS2.luc). The efficacy of ERE.PS2.luc induction via ERβ, on the 
other hand, was a significantly (P<0.0001) 9 times higher than that of ERE.vit2.luc (77.36 ± 
3.37 fold vs. 8.52 ± 0.45 fold, respectively). 
It is apparent from these results in HEK293 cells that the sensitivity of E2 transactivation of 
the ERE.PS2.luc system via ERβ was more sensitive when compared to other studies, which 
used different cell lines, as well as when compared to the study of Mortimer et al. [15], which 
used the same cell line but a different ERE [11–13,31].  These results further emphasise how 
important it is to take various factors, like cell types or response elements, into account when 
testing drug interactions, and to not only focus on drug concentrations. Furthermore, in the 
current study the ERE.PS2.luc system using HEK293 cells will be an ideal system to 
investigate the interaction and contribution of the phenolic compounds to the estrogenic 
activity of F3, which was shown to display robust ERβ transactivation [15].   
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Efficacy (fold induction) = 6.02  0.22 fold
LogEC50 = -11.09  0.17
Potency (EC50) = 8.14 x 10
-12 M
Efficacy (fold induction) = 8.52  0.45 fold
LogEC50 = -9.10  0.16
Potency (EC50) = 8.04 x 10
-10M
Efficacy (fold induction) = 6.22  0.14 foldns
LogEC50 = -10.92  0.08
ns
Potency (EC50) = 1.21 x 10
-11 M
Efficacy (fold induction) = 77.36  3.37 fold***
LogEC50 = -9.79  0.09
*
Potency (EC50) = 1.62 x 10
-10 M
 
Figure 4.4: Promoter reporter studies investigating ERα and ERβ dose response curves. A & B 
(pre-optimised protocol): HEK293 cells were transfected with pSG5-hERα (A) or pSG5-hERβ (B), 





M). C & D (post-optimised protocol): HEK293 cells were transfected with pSG5-hERα 
(C) or pSG5-hERβ (D), and PS2.ERE.luc and a pGL2 basic empty vector, and induced with 




M). Curve fitting: nonlinear regression with log 
(agonist) vs. response (three parameters). Statistical analysis: unpaired t-test, pre-optimised protocol 
vs post- 
4.2.3. Validation of optimised experimental protocols 
In previous studies, Mfenyana et al. [15] and Visser et al. [20], SM6Met was shown to be an 
ERβ agonist, an ERα antagonist and an inhibitor of E2-induced breast cancer cell 
proliferation. This extract (SM6Met) was subsequently separated into two fractions, namely, 
a polar (PF) and a non-polar fraction (NPF) [15]. Furthermore, the NPF, displaying the 
highest phytoestrogenic activity, was further fractionated into three fractions with fraction 3 
(F3) displaying the highest estrogenic activity via ERβ, when compared to the other NPF 
fractions [15].  
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Whilst the main focus of the current study is to investigate the contribution of the 7 major 
phenolic compounds previously identified in F3 to the estrogenic activity of F3, it forms part 
of a larger, ongoing investigation to identify the active components of the Cyclopia extracts. 
Therefore, to validate the protocols optimised in the current study, results from the optimised 
protocols were compared to that of previous laboratory protocols (pre-optimised protocols) 
used to obtain results in previous studies [15,20]. The SM6Met extract, the NPF and F3 were 
thus tested using the pre- and post-optimised protocols for both the proliferation assay and the 
promoter reporter assay. E2 was used as an agonist standard whereas fulvestrant (ICI 
182,780) was used as antagonist standard.  
4.2.3.1. Validation of optimised proliferation protocol using SM6Met, NPF and F3  
The SM6Met extract and the NPF have previously been shown to antagonise E2-induced cell 
proliferation of MCF-7 BUS cells, whereas F3 displayed no antagonistic activity. 
Furthermore, only F3, but not SM6Met and the NPF, displayed significant agonist activity 
[15]. To validate the optimised experimental protocol for MCF-7 BUS cell proliferation, the 
results obtained were compared to that of previous studies. 
The optimised cell proliferation protocol elicited a 3.23 ± 0.08 fold induction with 10
-9 
M E2 
(Figure 4.5 B) in comparison to the 1.74 ± 0.07 fold obtained with the pre-optimised protocol 
(Figure 4.5 A), which supports the results obtained during the optimisation procedure (Figure 
4.3 F). In the absence of E2, both the pre- and post-optimised protocols showed significant 
agonist activity for SM6Met, the NPF and F3. However, the activity of the extracts/fractions, 
in both the pre- and post-optimised protocol were not significantly different from that of 10
-11
 
M E2, with the exception of SM6Met in the post-optimised protocol, which displayed a 
significantly (P<0.0001) lower activity than 10
-11
 M E2. As expected, fulvestrant (ICI 
182,780) showed no agonist activity. 
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In antagonist mode, none of the extracts or fractions displayed antagonism of 10
-11
M E2, with 
either (pre-and post-optimised) protocol (Figure 4.5 C & D). Fulvestrant (ICI 182,780), 































































































































































































Figure 4.5: Cell proliferation studies investigating the agonist (A & B) and antagonist (C & D) 
activity of SM6Met, NPF, F3 & fulvestrant (ICI 182,780). Cells were induced with solvent (S), 






M) as agonist standard, SM6Met, NPF and F3 
(9.8µg/ml), and ICI 182,780 (10-10 M) as antagonist standard, both in (A & B) agonist (absence of E2) 
and (C & D) antagonist (presence of E2 10
-11 
M) mode. Both the pre-optimised laboratory protocol (A 
& C) and the post-optimised laboratory protocol (B & D) were investigated. Statistical analysis: One-
way ANOVA with Dunnett’s Multiple Comparisons Test as  post-test, all columns compared to 
solvent control set to 1 (black dotted line), *P<0.05, **P<0.001, ***P<0.0001, and 
extracts/fractions/compounds compared to E2 10
-11







Validation of the optimised cell proliferation assay indicated that this system was still not 
sensitive enough to obtain accurate results, since even after optimisation, F3 only displayed a 
induction of 2-fold. In addition, the favourable estrogenic profile of SM6Met previously 
reported was also not present, since neither SM6Met nor NPF displayed antagonism of E2-
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induced cell proliferation [15,20]. Consequently, the results were not comparable to previous 
studies. 
Furthermore, in the current study proliferative activity (measured with the MTT assay) was 
also compared to cell viability (measured with viable cell counting), since polyphenols have 
been shown to influence mitochondrial activity and, as MTT is metabolised via mitochondrial 
enzymes, may interfere with the MTT assay [32,33]. No difference between proliferative 
activity and cell viability (Figure 4.6), upon SM6Met induction was observed, which 
































Figure 4.6: Comparison of cell proliferation vs cell viability. MCF-7 BUS cells were induced with 
9.8µg/ml SM6Met to investigate and compare the effect of the extract on  proliferative activity (MTT 
assay) and cell viability (cell count).  Statistical analysis: t-test, solvent control set to 1 (black dotted 
line),*P<0.05, **P<0.001, ***P<0.0001, 
ns
no significant difference. 
4.2.3.2. Validation of optimised promoter reporter protocol using SM6Met, NPF and F3  
Following optimisation of the promoter reporter assay, a more sensitive system was 
established for ERβ by using the ERE.PS2.luc promoter reporter construct. To ensure that the 
favourable F3 characteristic of robust ERβ agonism, previously identified by Mortimer et al. 
[15], was maintained with the post-optimised protocol, F3 activity was compared in both the 
pre- and post-optimised protocols using both ER subtypes. Furthermore, in order to compare 
results from the current study to that of previous studies, SM6Met and the NPF were also 
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included to validate the pre- and post-optimised protocols in both agonist (Figure 4.7) and 
antagonist mode (Figure 4.8).  
Due to the significant (P<0.0001) difference in efficacy observed between ERα and ERβ for 
the post-optimised protocol (Figure 4.4 C & D), the activity of the compounds/extracts/ 






M) within each 
ER subtype protocol.  
The pre-optimised protocol, using ERE.vit2.luc, presented similar results compared to a 
previous study done by Mortimer et al. [15], with F3 displaying robust and significant 
(P<0.0001) ERβ agonist activity at 2.64 ± 0.13 fold induction (Figure 4.7 B) and no 
significant ERα activity (Figure 4.7 A). 
The post-optimised protocol, using ERE.PS2.luc, however, provided a significantly 
(P<0.0001) 10.5-fold increase in sensitivity via ERβ, with 10
-9 
M E2 producing a 62.10 ± 2.05 
fold induction (Figure 4.7 D) compared to the pre-optimised protocol, which only produced a 
5.92 ± 0.26 fold induction (Figure 4.7 B). Similarly, the post-optimised protocol via ERα also 
displayed a significant (P<0.001) 1.8-fold increase in sensitivity with 10
-9 
M E2.  
In the post-optimised protocol, F3 also showed a significantly (P<0.0001) more robust ERβ 
agonist activity compared to the pre-optimised protocol. This increase in sensitivity in the 
post-optimised protocol is not only apparent when comparing absolute fold induction (21.13 
± 3.62 vs 2.64 ± 0.13 fold induction), but also when comparing F3 to 10
-11 
M E2 (10 vs 1.5 
fold induction). Despite the increase in sensitivity in the post-optimised protocol, the rank 
order of F3 activation via ERβ remains similar, with F3 displaying comparable induction to 
that of 10
-10 
M E2 with both protocols (Figure 4.7 B & D).  
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The increased sensitivity with ERα observed in the post-optimised protocol has, however, 
now resulted in F3 displaying significant (P<0.0001) ERα agonist activity, in contrast to what 
was observed in the pre-optimised protocol and the Mortimer study [15]. Nonetheless, when 
comparing F3 fold induction to 10
-11 
M E2, it was significantly (P<0.05) lower in the post-
optimised protocol. In addition, in both protocols F3 induction is around 0.6-fold that of 10
-11 
M E2 (Figure 4.7 A & C).   
SM6Met and the NPF, on the other hand, displayed no significant agonist activity with either 
ER subtype for the pre-optimised protocol when compared to respective solvent treatments. 
These results did not correspond with the findings of Mortimer et al. [15], which showed 
significant ERα and β agonist activity with SM6Met and significant ERβ agonist activity with 
the NPF. With the post-optimised protocol, SM6Met displayed no significant agonist activity 
with either ER subtype, while the NPF only displayed significant ERα agonist activity 
(P<0.05). However, when conducting statistical analysis (unpaired t-test) to compare only the 
NPF to 10
-11
 E2 M, the NPF displayed significant (P<0.001) ERβ agonist activity via the post-
optimised protocol.   
 













































































































































































































Figure 4.7: Promotor reporter studies investigating the effect of E2, SM6Met extract, NPF and 
F3 on ERα (A & C) and ERβ (B & D) transactivation via vit2.ERE.luc (A & B) and 
PS2.ERE.luc (C & D)  in against mode. HEK293 cells were transfected with expression vectors 
pSG5-hERα/pSG5-hERβ, vit2.ERE.luc/PS2.ERE.luc and a pGL2 basic empty vector, and induced 




 M) as agonist standards, SM6Met, NPF and F3 
(9.8µg/ml), and ICI (10
-10
 M) as ER antagonist standard. Statistical analysis: One-way ANOVA with 
Dunnett’s Multiple Comparisons Test as  post-test, all columns compared to solvent control set to 1 
(black bar),* P <0.05, ** P< 0.001, *** P<0.0001, or compared to E2 10
-11








Antagonist mode was investigated in the presence of 10
-11
 M E2 with the induction of extract 
and fractions expressed relative to E2, which was set as 1. F3 displayed no antagonist activity 
but rather strong (P<0.0001) ERβ agonist activity, at 2.06 ± 0.38 fold induction (Figure 4.8 
B), with the pre-optimised protocol, thus appearing to have an additive effect via the ERβ 
subtype. F3, however, did display significant (P<0.001) levels of ERα antagonism with the 
pre-optimised protocol (Figure 4.8 A). This is in contrast to the results of Mortimer et al. 
[15], where no significant antagonism of F3 for either ER subtype was observed. 
In the post-optimised protocol, F3 displayed no antagonistic activity for either ER subtype, in 
accordance with results from Mortimer et al [15]. F3 did, however, display a significant 
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(P<0.0001) 9.48-fold higher ERβ agonist activity (Figure 4.8 D) in the presence of E2, which 
further substantiates F3’s strong additive ERβ agonist activity.  
In the pre-optimised protocol, neither SM6Met nor the NPF displayed significant antagonist 
activity in the presence of 10
-11
 M E2 via either ER subtype, which contradicts the ERα 
antagonistic profile of SM6Met and NPF previously identified by Mortimer et al [15].  
SM6Met did, however, present with significant (P<0.05) ERα antagonist activity (Figure 4.8 
C) in the post-optimised protocol, which corroborates previous studies [15,20]. The increased 
10
-11
 M E2 activity via ERα observed with the post-optimised protocol (Figure 4.7 C) could 
have resulted in the recovered ERα antagonist activity of SM6Met (Figure 4.8 C), which was 
not detected in the pre-optimised protocol (Figure 4.8 A). The increased sensitivity observed 
in the post-optimised protocol has, however, not resulted in the NPF displaying significant 
ERα antagonist activity. 
To summarise the validation of the promoter reporter protocol, F3 demonstrated strong and 
significant ERβ agonist activity in both the pre- and post-optimised protocol. However, the 
post-optimised protocol with ERE.PS2.Luc is a more sensitive protocol with F3 displaying a 
10-fold increase in ERβ agonist activity relative to 10
-11 
M E2 versus a 1.5-fold increase via 
ERE.Vit2.luc in the pre-optimised protocol. Therefore, for the current study, the post-
optimised protocol would be ideal to investigate the interaction and possible synergism of the 
7 major phenolic compounds identified in F3 in terms of ERβ activity [15].  
 


















































































































































Figure 4.8: Promotor reporter studies investigating the effect of E2, SM6Met extract, NPF, F3 
and fulvestrant (ICI) on ERα (A & C) and ERβ (B & D) transactivation via vit2.ERE.luc (A & 
B) and PS2.ERE.luc (C & D)  in antagainst mode. HEK293 cells were transfected with expression 
vectors pSG5-hERα/pSG5-hERβ, vit2.ERE.luc/PS2.ERE.luc and a pGL2 basic empty vector, and 
induced with E2 10
-11
 M, as well as SM6Met, NP and F3 (9.8µg/ml), and ICI (10
-10
 M) as ER 
antagonist standard, in the presence of E2 10
-11 
M. Statistical analysis: One-way ANOVA with 
Dunnett’s Multiple Comparisons Test as  post-test, all columns compared to E2 10
-11









As mentioned frequently throughout this chapter, a sensitive system is essential when testing 
drug interactions and possible synergism. This is especially important when testing 
phytocompounds since the interactions of the plant phenolic mixtures are complex and not 
fully understood. For example, it has been shown that compounds that do not display 
individual activity, could contribute to the bioavailability of active compounds within a 
mixture [7,34].  
Therefore, in the current study, various factors were investigated (including cell types, ER 
subtypes and ERE promoter reporter constructs, and optimisation of experimental 
Stellenbosch University  https://scholar.sun.ac.za
91 
 
procedures) in order to obtain an optimised protocol which is sensitive enough to detect small 
changes, produce accurate results and determine combinatory or possible synergistic effects. 
From the optimisation of the experimental protocols (cell proliferation assay and promoter 
reporter assay), it is clear that the promoter reporter assay is a more sensitive experimental 
system to test phytocompound interactions, since the efficacies of E2 via the promoter 
reporter assay (Figure 4.4) at 77.36 ± 3.37 and 6.22 ± 0.14 fold for ERβ and α, respectively, 
were higher than that of the cell proliferation assay (Figure 4.2) at 3.67 ± 0.08 fold.  
The promoter reporter assay also produced results similar to previous work done on F3, the 
focus of the current study, with robust ERβ agonism (10-fold compared to 10
-11
 M E2) and 
weak ERα agonism (0.6-fold compared to 10
-11
 M E2). Furthermore, since F3 also displayed 
no antagonistic activity via either ER subtype using the post-optimised protocol as shown in 
Mortimer’s study (Table 4.2), it was decided that further investigation would only be 
conducted in agonist mode. 
In addition, the agonist and antagonist activity of SM6Met and the NPF in the post-optimised 
promoter reporter assay, were also compared to that of Mortimer et al. [15], (Table 4.2). 
SM6Met only displayed comparable results to that of Mortimer et al., in antagonism mode 
via both ER subtypes, while the NPF results differed in all cases, except for ERβ antagonism. 
Furthermore, the antagonist results obtained for SM6Met and NPF via the MTT assay were 
also different from previous studies by Mortimer et al. [15], and Visser et al. [20]. These 
studies, however, used a higher concentration of E2 (10
-9 
M) to investigate antagonism, 
whereas the current study used 10
-11
 M E2, since this concentration of E2 is situated on the 
inflection point line (Figure 4.2 B). It could be that 10
-11 
M E2 did not display sufficiently 
strong agonist activity in order to detect the counter effects of the antagonist compounds. It 
could also be that degradation of phytoestrogens or important phenolic compounds in the 
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extract/fraction [35,36], some already identified [15,22,27], some yet to be discovered, could 
play a role. Combined these factors make it difficult to establish the possible causes of the 
change in SM6Met and the NPF’s activity. 
Table 4.2: Summary of validation outcomes of promoter reporter and proliferation (MTT) 
assays using SM6Met, the NPF and F3 which either display significant agonist (Ag) or 
antagonist (Antag) activity. Green represents results similar to whereas red represents results 
opposite to that of Mortimer et al [15].  































- Ag - - Ag Ag Ag - 
NPF - Ag - - - Ag Ag Ag - 












Antag Antag - - - - - Antag 
NPF - - Antag - - - - - Antag 
F3 Antag - - - - - - - - 
a




post-optimised protocol (ERE.PS2.luc) – Figure 4.7 A & B, Figure 4.8 A & B 
c 
summary from Mortminer et al. [15] 
d




post-optimised protocol (MTT) –  Figure 4.5 B & D 
f 
no agonist activity 
g 
no antagonist activity 
In summary, it was decided that the cell proliferation assay would not be used for further 
investigations. The promoter reporter assay, on the other hand, provided a more sensitive 
system and F3 results comparable to that of previous studies, and will therefore be used to 
further investigate the interaction and possible synergistic activity of the phenolic compounds 
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Chapter 5: Investigating the contribution of 
the major phenolic compounds identified in 
F3, to the robust ERβ activity of F3. 
  





Plants form part of our daily diet, and with increased evidence linking plant based food to 
improved health, as well as disease prevention, plants are not only considered a source of 
macronutrients (proteins, carbohydrates and fats), but also micronutrients (vitamins, minerals, 
dietary fibre, antioxidants and polyphenols) that have potential anti-inflammatory, anti-
diabetic and anti-carcinogenic properties [1–8].  
For many years plants have played a role in the healing rituals of indigenous and traditional 
populations such as in India, China and Africa [9–13]. The main focus of traditional 
phytomedicine is on using combination therapy to treat a patient as a whole while combating 
disease on multiple levels, instead of using a single well characterised active compound that 
is target specific [12,14]. This holistic approach of traditional medicine has transformed 
modern drug development and changed the way therapies for complex diseases, such as 
cancer, is approached [9,15].  
The higher effectiveness of plant extracts in comparison to single active plant derived 
compounds is thought to be due to the combinatorial and/or synergistic effects of the mixture 
of different active and supporting constituents [7,16–18]. The supporting constituents 
themselves could be pharmacologically inactive, but contribute to the stability, solubility 
and/or absorption rate of the active compounds [19]. The advantages of combinatorial or 
synergy approaches in cancer drug development are the possible multi-target effects that 
could result in the prevention of DNA damage, down regulation of oncogenes, up regulation 
of tumour-suppressor genes, and inhibition of pathways involved in the proliferation of 
defective cells [8,12,20–22].  
One plant of particular interest for the current study regarding possible novel nutraceutical 
development, that contains high levels of phenolic compounds and has displayed 




phytoestrogenic, anti-diabetic, anti-inflammatory and anti-mutagenic activity, is Cyclopia, 
which is more commonly known as Honeybush  [6,23–28]. Cyclopia forms part of the 
indigenous South African fynbos and is commercially available as a herbal tea [29,30]. In 
studies conducted by Mfenyana et al. [31] and Visser et al. [32], the sequential methanol 
extract from Cyclopia subternata harvesting M6 (SM6Met) was shown to be an ERβ agonist, 
an ERα antagonist and an inhibitor of E2-induced breast cancer cell proliferation. The current 
study, as mentioned in previous Chapters, focuses on F3, one of the fractions isolated from 
SM6Met [33].  
In Chapter 4, F3 was shown to display robust ERβ agonism, with a 10-fold increase in 
activity when compared to 10
-11 
M E2 (the physiological relevant concentrations of E2 in 
healthy women) [34]. Additionally, F3 displayed 1.6-fold lower activity than 10
-11 
M E2 via 
ERα. This demonstrates that F3 exhibits ER subtype selective activity, and highlights its 
potential as a nutraceutical in the treatment of estrogen-related cancer, especially considering 
that ERβ has been shown to inhibit the proliferative effects of ERα  [35–38].  
The phytoestrogenic activity of some of the individual phenolic compounds in Cyclopia, and 
subsequently in F3, was previously established [23,30]. However, the behaviour of these 
compounds in combination is still unknown. Therefore, the current study focuses on 
combining the 7 individual major phenolic compounds, identified and quantified in F3 [33], 
in order to determine their combinatorial or possible synergistic contribution to the 
favourable estrogenic profile of this fraction. The activity of the individual phytoestrogenic 
compounds was also investigated, in an attempt to determine their contribution to the 
estrogenic profile of F3.  
Following on from the optimisation and validation of estrogenic bioassays (Chapter 4), the 
promoter reporter assay was established as the more sensitive system to test phytocompound 




interactions and possible synergism, and therefore, the optimised protocol, in agonist mode, 
was used to investigate the phytoestrogenic activity of the phenolic compounds in the current 
Chapter.  
5.2. Results and discussion 
5.2.1. Evaluation of the estrogenic activity of reconstituted F3 (F3R) 
To evaluate and fully understand the nutraceutical potential of plant extracts, it is important 
to first understand the combinatorial role of all their components. This is, however, a difficult 
task when the activity and role of all the individual compounds are not yet known, as in the 
case of F3. Mortimer et al. [33], identified 15 phenolic compounds in F3 using  LCMS-MS, 
and quantified 7 of these phenolic compounds using qHPLC. Mangiferin, isomangiferin, 
scolymoside, p-coumaric acid and protochatechuic acid were identified as the major phenolic 
compounds present at the highest concentrations in F3. In his study, Mortimer also included 
two minor compounds in terms of mass, iriflophenone-3-C-glucoside and luteolin, since they 
were commercially available and could be detected in 9.8mg/ml* of F3. These 7 phenolic 
compounds
†
 were then classified by Mortimer as the major phenolic compounds in F3, an 
appellation we also use throughout the current study [33,39].  
The ideal approach to understand how F3 mediates its favourable ERβ agonist effect, would 
be to investigate all the major and minor phenolic compounds previously identified in F3 
[39]. However, as a starting point, only the 7 major phenolic compounds identified and 
quantified by Mortimer were used to reconstitute F3 (F3R), and to investigate their 
contribution to the robust ERβ agonist activity of F3, as demonstrated in Chapter 4. 
                                                          
*
 9.8mg/ml is a concentration used throughout our research group based on a study by Verhoog et al. [23][127].  
†
 The 7 phenolic compounds were purchased from different suppliers (see section 3.2.1). 




F3’s activity was validated prior to reconstituting the fraction. F3 displayed significant 
(P<0.001) ERβ agonist activity at 28.00 ± 2.78 fold induction (Figure 5.1 B) and no 
significant ERα activity at 1.23 ± 0.07 fold induction (Figure 5.1 A). Furthermore, when 






M E2), it displayed a significant 8.8-fold 
increase in activity via ERβ compared to 10
-11 
M E2, and no significant difference when 
compared to 10
-10 
M E2, whereas via ERα, F3 displayed a 1.12-fold decrease in activity 
compared 10
-11 
M E2. This is consistent with the findings from Chapter 4 and Mortimer et al., 
[33].  
The reconstituted F3 (F3R) was assembled according to the concentrations in Table 5.1, and 
the phytoestrogenic activity compared to the original F3, to determine if the major phenolic 
compounds are responsible for F3’s robust ERβ mediated activity. F3R (1x), showed no 
estrogenic activity via ERβ compared to solvent and was a significant (P<0.001) 28-fold 
lower than F3 (Figure 5.1 B). F3R (1x) also showed no significant ERα activity, as expected, 
since F3 also showed little ERα activity (1.23 ± 0.07 fold induction).  
Table 5.1: Phenolic content in F3 as identified in Mortimer et al. [33], which was used in 
reconstitution studies. 










 1.133 0.394 0.056 0.752 0.020 0.063 0.009 
1x F3R (M
b











































µg polyphenol in 9.8µg/ml F3 
b 
molar concentration of polyphenols corresponding to µg in 9.8µg/ml F3, as used in cell culture experiments 
To ensure that the lack of phytoestrogenic activity observed with F3R (1x) was not due to 
inaccurate sample preparation, LC-MS was performed and the phenolic content of F3R was 
compared to that in F3 (Figure S.1 & S.2). Data was processed using MassLynx V4.1 




software (Waters, USA) and the major phenolic compounds in F3R displayed similar peak 
areas and retention times to the compounds in F3, indicating that F3R was made up correctly 





































































































Figure 5.1: Promotor reporter studies investigating the effect of E2, F3 and F3R on ERα (A) and 
ERβ (B) transactivation in agonist mode. HEK293 cells were transfected with pSG5-hERα/pSG5-





(9.8µg/ml) and F3R reconstituted at 1x, 10x and 100x the concentrations of major phenolic 
compounds as identified in F3 (9.8µg/ml). Statistical analysis: One-way ANOVA with Dunnett’s 












P<0.001. Unpaired t-test, 







In addition, F3R was reconstituted at higher concentrations, as some of the phenolic 
compounds, like luteolin, have previously been shown to display phytoestrogenic activity 
[23,30,32,40,41]. F3R reconstituted at 10-fold (10x) its concentration in F3, F3R (10x), 
showed no significant activity via ERα and a 2.39-fold increase in activity via ERβ, although 
still not significant when compared to solvent. Conducting an unpaired t-test analysis, 
comparing only solvent to F3R (10x), a significant (P<0.01) induction was observed via ERβ, 
but not via ERα. The ERβ activity was, however, still a significant 11.72-fold lower than F3.   
Only at 100-fold (100x) the original concentration in F3 did F3R display significantly higher 
(P<0.001) fold induction via both ERα and ERβ, at 1.96 ± 0.09 and 74.44 ± 2.65 fold 
induction, respectively. A significant (P<0.001) 1.59-fold increase in activity was observed 
via ERα when compared to F3, and no significant difference when compared to 10
-9 
M E2. 




With ERβ, F3R (100x) displayed a significant (P<0.001) 2.66-fold increase in activity 
compared to F3, and a significant (P<0.01) 1.15-fold increase compared to 10
-9 
M E2. 
From these results, we can conclude that the 7 major phenolic compounds reconstituted at 
their original concentration as quantified in F3, do not recapitulate the activity of F3. This 
further accentuates the importance of the fraction as a whole and of including minor phenolic 
compounds. Only at 100x the concentration did F3R display significantly higher (P<0.001) 
agonist activity than F3 via both ER subtypes. It could be that the minor phenolic compounds 
not included in F3R play a supporting role (e.g. by influencing absorption, stability or export) 
in the phytoestrogenic activity of the major phenolic compounds in F3, and that without these 
minor compounds the major compounds in F3R are not present in the cells at a sufficient 
concentration to induce an estrogenic response. However, at higher concentrations, varying 
between 10
-6
 M and 10
-4 
M (Table 5.1), the major phenolic compounds are able to elicit an 
estrogenic response as seen with F3R (100x). These higher concentrations (Table 5.1) also 
corresponded to the concentration (10
-5 
M) of individual phenolic compounds, such as 
luteolin, previously shown to display phytoestrogenic activity within our research group [42]. 
To determine which of the 7 major phenolic compounds in F3R contribute to the activity 
observed at higher concentrations (10x F3R and 100x F3R), a further investigation was 
conducted regarding the individual activity of these compounds. 
5.2.2. Estrogenic activity of the phenolic compounds in F3R 
5.2.2.1. Estrogenic activity of the individual phenolic compounds in F3R 
Various societies globally are dependent on traditional medicinal plant sources for disease 
treatment due to poverty, lack of pharmaceutical manufacturing capacity or limited access to 
modern medicine [13,43]. Plant extracts consist of a variety of compounds that display 




complex interactions, and the adverse effects of traditional phytomedicine are not as well 
studied as that of synthetic drugs [9,19,44–47]. Therefore, to understand how plant extracts 
exert their effects as a whole, it is not only important to investigate the combinatorial effect 
of the constituent parts, but also the individual activity of all the compounds in order to 
establish safety and efficacy [19,44]. 
F3R did not display any phytoestrogenic activity when reconstituted at the same 
concentrations of major phenolic compounds as quantified in F3 (Table 5.1). At higher 
concentrations, however, a significant increase in agonist activity was observed with F3R. As 
mentioned before, luteolin has previously been shown to have phytoestrogenic activity, but at 
concentrations higher than that of luteolin in F3 (1 x 10
-5 
M vs 4.7 x 10
-8 
M, respectively) 
[23,42,48]. Therefore, to determine the individual activity profile and to discover which of 
the phenolic compounds could possibly contribute to F3R’s estrogenic activity at higher 
concentrations, the individual compounds were also investigated at increasing concentrations 
(1x, 10x, 100x).   
A decrease in sensitivity of the test system (especially via ERβ) was observed at this stage of 
the study, and various aspects were investigated including cell passage number, growth 
medium, DNA plasmid quality, as well as incubator functionality, but no deviations or 
decrease in quality was noticed. Despite the decrease in sensitivity and ongoing search for the 
possible cause, the rank order of F3 activity compared to the E2 controls remained similar. 
Specifically as seen in Figure 5.2, F3 elicited a response that was not significantly different 
than 10
-11 





M E2 via ERβ. 
None of the 7 phenolic compounds displayed significant estrogenic activity at 1x their 
concentration in F3 (Figure 5.2 A – J & Figure 5.3 A – D). This concurs with findings from 




Mortimer’s study [33] and was expected since F3R (1x) displaced no activity (Figure 5.1). In 
addition, isomangiferin, scolymoside, iriflophenone-3-C-glucoside, p-coumaric acid and 
protocatechuic acid also did not display any significant phytoestrogenic activity at increased 
(10x and 100x) concentrations (Figure 5.2 A – J). Although these phenolic compounds did 
not display phytoestrogenic activity in our system, some of them (protocatechuic acid and p-
coumaric acid) have been shown to possess anti-carcinogenic and chemo-preventative 
properties in breast cancer cell lines [49–52]. 
Mangiferin and luteolin were the only two phenolic compounds that demonstrated 
phytoestrogenic activity in our test system at increased concentrations (Figure 5.3 A – D). At 
the time, mangiferin’s phytoestrogenic activity was a novel finding [30,33,42]. 
Mangiferin (10x) displayed a significant (P<0.01) increase in activity via both ERα (Figure 
5.3 A) and ERβ (Figure 5.3B), at 1.26 ± 0.03 and 3.44 ± 0.11 fold induction, respectively. 
Even so, mangiferin (10x) still displayed a significantly (P<0.001) lower activity when 
compared to that of F3 via ERβ (Figure 5.3 B), but no significant difference via ERα (Figure 
5.3 A). Luteolin, on the other hand, displayed no significant estrogenic activity at 10x its 
concentration in F3 via either ER subtype (Figure 5.3 C & D). 


































































































































































































































































































































































































































































Figure 5.2: Promotor reporter studies investigating the effect of E2, F3 and the individual major 
phenolic compounds identified in F3 via ERα (A, C, E, G & I) and ERβ (B, D, F, H & J) 
transactivation in agonist mode. HEK293 cells were transfected with pSG5-hERα/pSG5-hERβ), 




M), F3 (9.8µg/ml) and 
individual phenolic compounds at 1x, 10x and 100x their concentrations as identified in 9.8µg/ml F3 
(Table 5.1): isomangiferin (A & B), scolymoside (C & D), iriflophenone-3-C-glucoside (E & F), p-
coumaric acid (G & H) & protocatechuic acid (I & J). Statistical analysis: One-way ANOVA with 



















Mangiferin and luteolin, at 100x their concentration in F3, however, both presented a 
significant (P<0.001) increase in activity via both the ER subtypes. Compared to F3, 
mangiferin displayed a small, yet significant (P<0.05), 1.16-fold increase in activity via ERα, 
and a significant (P<0.05) 1.16-fold lower activity via ERβ. Luteolin (100x) demonstrated 
robust ER agonist activity with a significant (P<0.001) 1.43- and 1.44-fold increase in 




































































































































































































 Figure 5.3: Promotor reporter studies investigating the effect of E2, F3 and the individual 
phenolic compounds, mangiferin and luteolin, identified in F3 via ERα (A & C) and ERβ (B & 
D) transactivation in agonist mode. HEK293 cells were transfected with pSG5-hERα/pSG5-hERβ), 




M), F3 (9.8µg/ml) and 
individual phenolic compounds at 1x, 10x and 100x their concentrations as identified in 9.8µg/ml F3 
(Table 5.1): mangiferin (A & B) and luteolin (C & D). Statistical analysis: One-way ANOVA with 



















To conclude, none of the 7 individual major phenolic compounds displayed significant 
estrogenic activity at their concentration in 9.8µg/ml F3R. These results correlates with the 
findings of Mortimer et al. [33]. In addition, mangiferin and luteolin were the only two 
phenolic compounds that displayed phytoestrogenic activity at higher concentrations. The 
estrogenic activity of mangiferin was a novel discovery at this stage of the current study, as 
no articles or papers, to our knowledge then, had been published regarding mangiferin’s 
estrogenicity, in contrast to luteolin, which had shown estrogenic activity via both ER 
subtypes in various experimental systems [23,30,42,53–55].  
5.2.2.2. Detailed investigation of estrogenic activity of the estrogenic compounds, 
mangiferin and luteolin 
In the literature, mangiferin and luteolin display a variety of health benefits including 
decreasing the prevalence of metabolic disorders, cardiovascular protective properties, and 
combating various cancers on multiple levels [56–62]. In breast cancer studies, luteolin has 
been shown to act like an aromatase inhibitor, by down regulating aromatase transcription 
and enzyme activity, to suppress ERα expression, and to inhibit MCF-7 breast cancer cell 
growth [40,55,57,62]. Mangiferin has been shown to decrease cell proliferation and increase 
apoptosis, which consequently resulted in the decrease in cell viability of ER-positive and 
ER-negative breast cancer cell lines [63–65].  
ER signalling may be either ligand-dependent or ligand-independent, and estrogenic 
compounds may mediate their effect directly through the ER, or by binding to other receptors 
and influencing other signalling pathways [47,55,66,67]. Therefore, to determine mangiferin 
and luteolin’s receptor-mediated mode of action, an ER binding assay was performed to 
establish whether these phenolic compounds would compete with radio-labelled 17β-estradiol 
(
3
H-E2) for binding to the ER subtypes. 




The specific binding‡ of unlabelled 10
-5 
M E2, mangiferin (100x) and luteolin (100x) were 
determined, and the specific binding of the phenolic compounds were expressed relative to 
E2, set to 100% (Figure 5.4). Mangiferin and luteolin were able to displace 20 nM 
3
H-E2 from 
both ER subtypes, however, not to the same extent as 10
-5 
M E2.  
Luteolin’s displacing of 
3
H-E2, compared to E2, was significantly (P<0.001) lower for both 
ERα and ERβ, at 47% and 31%, respectively. In a study conducted by Verhoog et al. [42], 
luteolin displaced more than 50% of 
3
H-E2 from both ER subtypes with a higher 
displacement percentage for ERβ. The concentration of luteolin in Verhoog’s study was, 
however, double the concentration used in the current study. The concentration difference 
could therefore be the cause of luteolin’s lower binding capacity observed with ERβ in the 
current study [42]. 
Mangiferin’s ability to displace 
3
H-E2 from ERα and ERβ was also significantly (P<0.01) 
lower than E2, yet, significantly (P<0.05) higher than luteolin via ERα. The only previous 
indication of mangiferin’s ability to bind to the ER, is in a study by Kitalong et al. [68], were 
10
-3 
M mangiferin (a concentration approximately 4-fold higher than used in the current 
study) exhibited 50% displacement of fluorescence-labelled E2 from ERα. Although the 
experimental system is different in the current study, mangiferin has, to our knowledge, never 
before been shown to display binding activity via ERβ [30,42], and is therefore this is a novel 
finding.  
                                                          
‡
 Specific binding = total binding – non-specific binding [128] 









































Figure 5.4: Whole cell binding studies investigating the specific binding activity of E2, luteolin 
and mangiferin. COS-1 cells were transfected with pSG5-hERα or pSG5-hERβ), and incubated with 
unlabelled E2 (10
-5 
M), 2.68 x 10
-4
 M mangiferin (100x) or 4.74 x 10
-6
 M luteolin (100x), in the 
presence of tritiated E2 (20 nM). Statistical analysis: One-way ANOVA with Dunnett’s Multiple 













The ability of a ligand to bind to the ER is not necessarily related to that ligand’s ability to 
mediate an estrogenic response [30,55]. From the previous result, it is clear that both 
mangiferin and luteolin bind to the ERs, however, to determine if these phytoestrogenic 
compounds mediated their transcriptional effect through the ER subtypes, fulvestrant (a full 
ER antagonist also known as ICI 182,780 [69,70]) was added in combination with mangiferin 
(100x) or luteolin (100x).  
A small, yet significant (P<0.05), decrease in activity was observed for both mangiferin 
(Figure 5.5 A) and luteolin (Figure 5.5 C) via ERα when fulvestrant (ICI) was added. With 
ERβ, on the other hand, addition of fulvestrant resulted in a significant (P<0.001) 2.76- and 
2.32-fold decrease in mangiferin and luteolin’s activity, respectively (Figure 5.5 B & D). 
Even though the concentration of ICI (10
-10 
M) was relatively low compared to the 
concentrations of mangiferin (2.68 x 10
-4 
M) and luteolin (4.74 x 10
-6 
M), ICI was still able to 
decrease the estrogenic activity of these two phenolic compounds (by downregulating the 
ERs [70]), indicating that  mangiferin and luteolin mediate their estrogenic effect by binding 
to the ERs.  





























































































































































Figure 5.5: Promotor reporter studies investigating the effect of the estrogenic phenolic 
compounds (mangiferin and luteolin) via ERα (A & C) and ERβ (B & D) transactivation in the 
absence and presence of an ER antagonist. HEK293 cells were transfected with pSG5-hERα/pSG5-
hERβ, ERE.PS2.luc and a pGL2 basic empty vector, and induced with 2.68 x 10
-4 
M mangiferin 
(100x) (A & B), and 4.74 x 10
-6
 M luteolin (100x) (C & D), in the absence and presence of 10
-10 
M 
fulvestrant (ICI 182,780). Statistical analysis: One-way ANOVA with Dunnett’s Multiple 














In addition, the efficacy and potency of mangiferin and luteolin were also investigated as a 
prelude to determining the potential combinatorial or synergistic activity of these estrogenic 
phenolic compounds. Unfortunately, the potency and efficacy of mangiferin could not be 
obtained (Figure 5.6 A & B), since the compound did not attain maximal response at the 
concentrations used, and even though higher concentrations were investigated, the solubility 
of mangiferin reached saturation in the medium.  
Luteolin, on the other hand, displayed a biphasic response (a phenomenon also observed with 
estrogen [71]) with a dose dependent increase in activity up till 140x its concentration in F3R 
(6.63 x 10
-6
 M), after which a decrease in activity was observed (Figure 5.6 C & D). 
Although there is a significant (P<0.001) 17-fold difference in efficacy between ERα and 









M, respectively (Figure 5.6 C & D). Similar results were obtained from another 
study by Verhoog et al. [23], which established a potency of 6.78 x 10
-6
 M via ERα and 1.23 
x 10
-5 
M via ERβ for luteoin, within their experimental model. Relative to E2, luteolin acts as 
a partial ER agonist with reduced potency, since luteolin displayed significantly (P<0.05) 
lower efficacy and potency than E2 (Figure 5.6 E & F) via both ERs. 
































































Efficacy (fold induction) = 3.12  0.43 fold#
Log EC50 = -5.36  0.04
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Efficacy (fold induction) = 52.97  4.02 fold***, ##
Log EC50 = -5.35  0.01
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Efficacy (fold induction) = 6.22  0.14 fold
LogEC50 = -10.92  0.08






























Efficacy (fold induction) = 77.36  3.37 fold***
LogEC50 = -9.79  0.09
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Figure 5.6: Promoter reporter studies investigating the efficacy (maximal fold induction) and 
potency (EC50) of mangiferin, luteolin and E2 via ERα (A, C & E) and ERβ (B, D & F). HEK293 
cells were transfected with pSG5-hERα or pSG5-hERβ, and PS2.ERE.luc and a pGL2 basic empty 
vector, and induced with increasing concentrations of mangiferin: 2.68 x 10
-6
 – 5.36 x 10
-4 
M (A & 
B), luteolin: 2.37 x 10
-6 
– 7.10 x 10
-6




 M (E & F). Curve fitting: 
nonlinear regression with log (agonist) vs. response (three parameters). Statistical analysis of efficacy 
and potency: unpaired t-test, ERα vs ERβ, *P<0.05, **P<0.01, ***P<0.001 and 
ns
no significant 











Luteolin has been shown to display estrogenic and anti-estrogenic activity in different 
experimental systems including luciferase based ERE-containing promoter reporter assays, 
ER binding assays and cell proliferation assays [23,30,42,57]. Luteolin has also been shown 
to inhibit other receptors including epidermal growth factor receptor (EGFR), insulin-like 
growth factor 1 receptor (IGF-1R) and related signalling pathways, which indirectly affects 
ERα mediated activity [54,62,66,72]. The current study only investigated luteolin’s ability to 
bind to the ER’s and to mediate an estrogenic response via the promoter reporter assay. To 
fully understand luteolin’s potential and contribution to the estrogenic profile of F3, more 
research is needed. 
In contrast, little is known about mangiferin’s estrogenic mode of action and many studies 
have claimed that mangiferin demonstrates no estrogenic activity in their experimental 
systems [23,30,32,42,68]. However, in a recent study by Wilkinson et al. [73], mangiferin (at 
3 x 10
-4 
M, a concertation similar to mangiferin (100x) in the current study) displayed ERα 
mediated estrogenic activity but no ERβ activity in COS-1 cells transfected with either 
pRST7-ERα or pRST7-ERβ, and a pGL2-TATA-Inr-Luc-3XERETATALuc reporter 
construct. These findings contradict the strong ERβ mediated estrogenic activity of 
mangiferin (2.68 x 10
-4
 M) observed in the current study.  
5.2.2.3. Identifying the phenolic compounds contributing to the activity of 100x F3R  
Investigation of the individual phytoestrogenic activity of the 7 major phenolic compounds 
confirmed that mangiferin and luteolin were the only two phenolic compounds in F3R that 
displayed individual estrogenicity at higher concentrations. Thus, to determine mangiferin 
and luteolin’s contribution to the robust ERα and β agonist activity of F3R (100x), F3R was 
reconstituted with these estrogenic phenolic compounds at 100x their concentration, 
respectively, while the remaining phenolic compounds were maintained at 1x their 




concentration in F3. Thus, when mangiferin was added at 100x, luteolin would only be added 
at 1x its concentration together with the other phenolic compounds, and vice versa.  The 
activity of the newly constructed fractions, F3R Man 100x (Figure 5.7 A & C) and F3R Lut 
100x (Figure 5.7 B & D), were subsequently compared to F3R as well as to their respective 
phenolic compounds at increasing concentrations.  
Prior to comparing the newly reconstituted fractions, F3R was initially compared to the 
respective phenolic compounds, mangiferin and luteolin, alone at increasing concentrations. 
F3R (1x), mangiferin (1x) (Figure 5.7 A & B) and luteolin (1x) (Figure 5.7 C & D) displayed 
no significant agonist activity via either ER subtype. Although, F3R (10x), mangiferin (10x) 
and luteolin (10x) also did not display significant activity via either ER subtype, via ERβ, 
both F3R (10x) and mangiferin (10x) presented with a circa 2-fold increase in activity (Figure 
5.7 B). Statistical analysis (not shown) in the absence of F3R (100x), F3R Man (100x) and 
mangiferin (100x), showed a significant difference (P<0.001) between 1x and 10x F3R. 
Furthermore, a significant difference (P<0.01) was then also observed between 1x and 10x 
mangiferin, with no significant difference between F3R (10x) and mangiferin (10x), 
indicating that mangiferin (10x) was potentially responsible for the 2.39 ± 0.16 fold induction 
observed with F3R (10x) via ERβ.  
In addition, in a separate experiment, F3R was also reconstituted with each of the 7 major 
phenolic compounds at 10x their concentration, respectively, while the remaining phenolic 
compounds were maintained at 1x their concentration in F3 (Table 5.1 & Figure S.3). Only 
F3R Man (10x) displayed comparable results to F3R (10x) via ERβ at 3.80 ± 0.12 and 3.96 ± 
0.17 fold induction, respectively, confirming mangiferin’s (10x) role in F3R (10x) induction 
via ERβ. Via ERα, F3R (10x) and F3R Man (10x) were also the only two reconstituted 
mixtures that displayed significant (P<0.05) estrogenic activity, however, the overall fold 
induction for ERα was very low and there was no significant difference between any of the 7 




newly reconstructed F3Rs (10x) and F3R (10x). Since the phenolic compounds are very 
expensive, it was decided at this point in the study to only focus on the phenolic compounds 
that contributed to the estrogenic activity observed with F3R (100x). 
Comparing mangiferin (100x) with F3R (100x), a significant (P<0.001) 1.61- and 1.99-fold 
decrease in activity was observed via ERα (2.14 ± 0.08 vs 1.33 ± 0.04 fold induction) and 
ERβ (74.44 ± 2.65 vs 37.47 ± 2.20 fold induction) (Figure 5.7 A & B), respectively. Luteolin 
(100x) also displayed lower activity than F3R (100x), with a significant (P<0.05) 1.20- and 
1.70-fold difference via ERα and ERβ, respectively (Figure 5.7 C & D). Suggesting that 
neither mangiferin (100x) nor luteolin (100x) alone could recapitulate the activity of F3R 
(100x). 
Subsequently, the activity of the newly reconstituted fraction, F3R Man (100x), was 
compared to F3R (100x) and mangiferin (100x). Via ERα, F3R Man (100x), like Man (x100), 
displayed no significant phytoestrogenic activity, which was significantly (P<0.01) lower 
than that of F3R (100x). However, in contrast, via ERβ there was no significant difference 
observed between F3R Man (100x) and F3R (100x). Mangiferin (100x) on its own, on the 
other hand, displayed significantly (P<0.01) lower ERβ activity compared to F3R Man 
(100x).  
Comparing the response of the other newly reconstituted fraction (F3R Lut (100x)) to that of 
F3R (100x), a significant (P<0.01) difference was observed via ERα and no significant 
difference via ERβ. There was also no significant difference observed between luteolin 
(100x) and F3R Lut (100x) via either ER subtype, although Lut (100x) was significantly 
(P<0.05) lower than F3R (100x) via both ERβ and ERα.  













































































































































































Figure 5.7: Promotor reporter studies comparing the activity of F3R, the newly reconstructed 
fractions, F3R Lut 100x and F3R Man 100x, and the estrogenic phenolic compounds, magiferin 
and luteolin, via ERα (A & C) and ERβ (B & D) transactivation in agonist mode. HEK293 cells 
were transfected with pSG5-hERα/pSG5-hERβ), ERE.PS2.luc and a pGL2 basic empty vector, and 
induced with F3R (1x, 10x and 100x), mangiferin (1x, 10x & 100x) and F3R Man 100x (A & B), as 
well as luteolin (1x, 10x & 100x) and F3R Lut 100x (C & D). Statistical analysis: One-way ANOVA 
with Dunnett’s Multiple Comparisons Test as  post-test, all columns compared to solvent control set 






P<0.001, or the activity of F3R (100x), newly reconstituted 







Assessing the results for ERα, it is evident that neither mangiferin nor luteolin at 100x their 
concentration in F3R, individually or combined with other polyphenols (F3R Man 100x & 
F3R Lut 100x), are potentially responsible for the ERα agonist activity observed with F3R 
(100x). Mangiferin (100x) and F3R Man 100x displayed no significant estrogenic activity, 
and their responses were significantly (P<0.01) lower than F3R (100x). Luteolin (100x) and 
F3R Lut 100x, on the other hand, displayed significant (P<0.001) agonist activity with no 
significant difference observed between them, however, the activity of luteolin (100x) and 
F3R Lut 100x was significantly (P<0.05) lower than that of F3R (100x). These results 
suggests that, even though luteolin appears to be the main estrogenic contributor, one or more 




of the other major phenolic compounds, at 100x their concentrations, are also contributing to 
F3R (100x)’s agonist activity via ERα.  
For ERβ, it is apparent that mangiferin (10x) is responsible for the activity observed with 
F3R (10x). However, at 100x their concentration in F3R, the two individual phytoestrogenic 
phenolic compounds (luteolin and mangiferin) displayed significantly (P<0.01) lower activity 
than observed with F3R (100x). Yet, when combined with the rest of the major phenolic 
compounds, F3R Lut 100x and F3R Man 100x displayed no significant difference compared 
to F3R (100x). This suggests that either both mangiferin and luteolin contribute to F3R 
(100x)’s robust agonist activity in an additive or possibly synergistic manner, or that the non-
estrogenic compounds in F3R (isomangiferin, scolymoside, iriflophenone-3-C-glucoside, p-
coumaric acid and protocatechuic acid) are enhancing the phytoestrogenic activity of 
mangiferin and luteolin.  
Consequently, F3R was again reconstituted with the 5 non-estrogenic phenolic compounds at 
1x their concentrations in the F3 fraction, and with both mangiferin and luteolin at 100x their 
concentration, to examine if an increase in activity is observed when both the estrogenic 
phenolic compounds are present at 100x their concentration (Figure 5.8 A & B). 
F3R (Man + Lut) 100x, like F3R Man 100x and F3R Lut 100x, displayed significantly 
(P<0.05) lower ERα activity compared to F3R (100x) (Figure 5.8 A). F3R Man 100x was 
also a significantly (P<0.05) 1.34-fold lower than F3R (Man + Lut) 100x, whereas F3R Lut 
100x displayed no significant difference from F3R (Man + Lut) 100x, again demonstrating 
that, in contrast to luteolin, mangiferin is not the main contributor to the estrogenic activity of 
F3R (Man + Lut) 100x via ERα. Furthermore, the newly reconstructed fractions (F3R (Man + 
Lut) 100x, F3R Man 100x and F3R Lut 100x) and F3R (100x) displayed no significant 




difference in activity via ERβ, indicating that mangiferin and luteolin’s role in F3R’s activity 
via ERβ may be interchangeable (Figure 5.8 B). 































































































Figure 5.8: Promotor reporter studies comparing the activity of F3R, the newly reconstructed 
fractions, F3R (Man + Lut) 100x, F3R Lut 100x and F3R Man 100x via ERα (A) and ERβ (B) 
transactivation in agonist mode. HEK293 cells were transfected with pSG5-hERα/pSG5-hERβ), 
ERE.PS2.luc and a pGL2 basic empty vector, and induced with F3R (100x), F3R (Man + Lut) 100x, 
F3R Lut 100x and F3R Man 100x, as well as individual estrogenic phenolic compounds, mangiferin 
(100x) and luteolin (100x). Statistical analysis: One-way ANOVA with Dunnett’s Multiple 







P<0.001. Activity of F3R (100x) compared to the newly reconstituted fractions or 






P<0.001, and F3R (Man + Lut) 100x 







In addition, subtraction of the individual phenolic compounds from 100x F3R were 
conducted to further validate mangiferin and luteolin’s involvement in the activity observed 
in 100x F3R, and to investigate the role of the non-estrogenic phenolic compounds (Figure 
S.4). Since the compounds are expensive and limited, this study was only conducted via ERβ. 
Unfortunately, mangiferin lost its ER agonist activity, and the activity observed in the 100x 
F3R was only due to 100x luteolin (Figure S.4).  
One of the limitations of cell culture experimental systems is the cell’s vulnerability to 
external changes, such as nutrition, humidity, temperature, CO2 and pH, which could 
influence the cell’s uptake of nutrients and hormones [74–77]. Apart from the fragility of the 
cells, phenolic compounds are also susceptible to external factors, such as storage conditions, 
temperature, exposure to light and oxygen, and the composition and quality of the solvent or 
medium. These various factors could cause deprotonation, oxidation or degradation of the 




compounds and could results in the loss of function or desired activity [78–85]. Investigating 
the possible causes for the loss of mangiferin’s once robust ERβ agonist activity, the 
composition of the cell culture medium and the structural integrity of the compound was 
investigated.  
Within our research group, it was noted that the pre-made phenol red medium transitioned 
colour from red to a pink-red colour during storage, indicating that the pH of the medium 
shifted from neutral to alkaline [86,87]. The pH of the medium was always adjusted to 7.2 
during preparation, but after being stored for a few weeks (2 weeks and longer), the pH of the 
pre-made medium tested at ≥9. The general protocol for medium preparation was adapted (by 
changing the sodium bicarbonate concentration), with the purpose of ensuring more stable 
medium pH levels during storage and cell culture maintenance. At the time, this change in 
protocol was not thought to be a contributing factor to the observed change in phytoactivity 
of mangiferin, since the activity of the E2 controls did not change. However, recent 
publications have indicated the importance of pH in the bio-activity of mangiferin [85]. The 
ramifications of pH drifting will be further addressed in the conclusion. 
Another possible cause for mangiferin’s loss of activity was thought to be due to the break-
down of the compound during storage. LC-MS (Figure S.5) and NMR (Figure S.6) were used 
to investigate this theory [88–91]. There was, however, no structural degradation observed 
between any of the mangiferin stocks (26/09/14, 25/10/14, 07/04/15 and 16/06/15)§, since 
they all displayed the expected molecular mass of 422g/mol and molecular formula of 
C19H18O11, while the 1H-NMR signals correlated with previous studies [90,92–94]. 
Interestingly, an additional structure was observed in the mangiferin sample with a molecular 
mass of 436g/mol and molecular formula of C20H20O11 (Figure S.5). NMR results (Figure 
S.7), and findings from literature, confirm that the second compound was homomangiferin 
                                                          
§
 Mangiferin stocks were labelled according to the date the compounds were received from the manufacturer.  




[88,89,91]. In addition to testing the bought mangiferin stocks, mangiferin recently isolated 
from Cyclopia (Gerderblom et al. 2016, unpublished) was also included in the NMR study. 
Homomangiferin was, surprisingly, not detected in Gelderblom’s sample. Like mangiferin, 
not much is known about homomangiferin’s possible phytoestrogenic activity.  
Findings from this section highlight the importance of all the compounds in F3R, and 
subsequently F3. Even though mangiferin and the non-estrogenic phenolic compounds did 
not show a contribution to F3R’s activity in the subtraction study (Figure S.4), their 
contribution to F3’s activity should not be dismissed.   
5.2.3. Combination of the estrogenic compounds, mangiferin and luteolin, to 
investigate possible interaction 
There are different methods to investigate possible combinatorial activity or synergism 
including the median effect analysis, response surface analysis, combination index, and the 
isobole method of Berenbaum [18,95–98]. The latter is one of the easier methods to test for 
additive/synergistic activity since it is a demonstrative method and it is also independent of 
the mechanisms of action [18].  
The isobologram, by Tallarida et al. [96], is a more simplified approach to the isobole method 
and uses fixed ratio combinations of the drug EC50’s instead of a range of drug EC50 
combinations. This is a more cost effective approach, since less of the compounds are used.  
It was, however, not possible to combine mangiferin and luteolin at a fixed ratio manner (as 
demonstated by Tallarida et al. [96]), due to the loss of mangiferin’s once robust 
phytoestrogenic activity. A different approach to this complication was to use increasing 
concentrations of mangiferin combined with the EC50 concentration (4 x 10
-6 
M) of luteolin, 
which is similar to luteolin (100x) (Figure 5.6 C & D), with the hope of mangiferin regaining 
activity in the presence of luteolin.  




Luteolin (100x) displayed phytoestrogenic activity via both ERα and ERβ, at 8.83 ± 0.39 and 
24.10 ± 1.05 fold induction, respectively (Figure 5.9 A & B). Mangiferin (100x), on the other 
hand, displayed no estrogenic activity. The activity observed with the combination of the two 
polyphenols, displayed no significant difference when compared to luteolin (100x) alone, 
suggesting that luteolin is the only polyphenol out of the 7 major phenolic compounds that 
displayed phytoestrogenic activity at this stage of the study, validating previous results 
(Figure S.4). 












































































Figure 5.9: Promoter reporter studies investigating the combined effect of mangiferin and 
luteolin on ERα (A) and ERβ (B) transactivation in agonist mode: HEK293 cells were transfected 
with pSG5-hERα/pSG5-hERβ, ERE.PS2.luc and a pGL2 basic empty vector, and induced with 4.74 x 
10
-6
 M luteolin (100x) combined with increasing concentrations of mangiferin, 2.68 x 10
-5
 – 5.36 x 10
-
4 
M (10x – 200x). All compounds normalised to solvent, set as 1. Statistical analysis: One-way 








Even though the estrogenic activity of mangiferin could not be restored in the presence of 
luteolin, mangiferin should not be dismissed as a possible candidate to F3R’s (and 
subsequently F3’s) agonist activity as recent studies have now demonstrated that mangiferin 
has phytoestrogenic potential [68,73]. Furthermore, to fully demonstrate the possible 
combinatorial or synergism potential of F3R, the non-estrogenic phenolic compounds should 
also be considered in future studies, since the estrogenic phenolic compounds (mangiferin and 
luteolin), on their own, previously displayed lower activity compared to F3R in the current 
study (Figure 5.8).  





Traditional medicine, which gained knowledge through observing nature, formed the 
foundation upon which modern medicine is built [99,100]. The development and 
improvement of chemical and analytical techniques provided insight into the phytochemical 
composition of medicinal plants, and created a platform for the identification, isolation and 
synthesis of single, well characterised, active compounds that are target specific [14,15,101]. 
However, as modern medicine evolved, new challenges arose (drug resistance, dangerous 
side effects and decreased drug efficacy) and a renewed approach to therapy development is 
needed to overcome these problems  [102–106].  
Medicinal plants consist of various phytochemicals that interact in complex molecular 
networks to achieve stability, as well as to enhance the bioavailability and potency of the 
active compounds [12,19,107]. Whole plant extracts and combination therapies have been 
shown to be more effective than mono-therapies (which only focus on single active or target 
specific compounds in plant extracts) in treating multifaceted diseases, such as cancer 
[33,62,95,108–110]. Nevertheless, medicinal plants need to be used with caution, since often 
their mechanism of action is not as well studied compared to mono-therapies and synthetic 
drugs [45,46,111]. Perhaps, combining the knowledge of traditional plant medicine with the 
support of scientific methods would produce intelligent drug mixtures capable of overcoming 
the current limitations of modern medicine [9,112].  
Cyclopia, indigenous to South Africa’s fynbos biome and traditionally used as a herbal tea, 
has gained growing interest for its health benefits, and various studies have demonstrated it 
antioxidant, anti-inflammatory, -diabetic and -mutagenic properties as well as chemo-
preventive activity [6,24–28,32,33]. This potential multi-action activity of Cyclopia makes it 
an ideal candidate for nutraceutical, and possible pharmaceutical, therapy development. The 




current study forms part of a larger, ongoing investigation to identify the active and 
contributing components of the Cyclopia extracts and fractions previously isolated [23,31–
33,42], with the purpose of creating the ideal nutraceutical to combat estrogen-related 
diseases, and avoid drug resistance, toxicity and side effects.  
Cyclopia extracts and fractions, like most plant material, consist of a vast variety of phenolic 
compounds. Some of these compounds have previously been identified in our research group 
[23,32,33] and by other groups [113–116], however, their combined activity and interactions 
have not yet been established. The main interest of the current study, therefore, was to 
investigate the combinatorial activity of some phenolic compounds identified and quantified 
in F3, a fraction isolated from the Cyclopia subternata extract, SM6Met [30,33]. What 
distinguished F3 from the other SM6Met fractions was its robust ERβ agonist activity [33]. 
ERα is known to induce cell proliferation, whereas ERβ has shown anti-proliferative activity 
by antagonising ERα, and therefore, compounds that mediate their response via ERβ is of 
great interest in the development of treatments for estrogen-related diseases [35–38].  
As mentioned previously, only the 7 major phenolic compounds were used as a starting point, 
to investigate their contribution to F3’s robust ERβ agonist activity [33]. Some of these 
phenolic compounds, such as luteolin, have previously shown phytoestrogenic activity in 
different experimental systems [30,42,53,73]. Interestingly, however, when F3 was 
reconstituted using the 7 major phenolic compounds at their concentrations in F3, no 
significant ER activity was observed (Figure 5.1). Possible reasons could be: (1) the minor 
phenolic compounds, alone or in combination, are responsible for F3’s estrogenic activity, (2) 
the minor compounds create a supportive environment for the active major compounds to 
elicit a response, or (3) there are still unidentified major phenolic compounds in F3 
responsible for its phytoestrogenic activity. 




However, when F3 was reconstituted at 100x its concentration (F3R (100x)), a significant 
(P<0.001) increase in activity was observed via both ER subtypes. In addition, F3R (100x)’s 
activity was a significant 1.59- and 2.66-fold higher than that of F3, via ERα and ERβ, 
respectively (Figure 5.1). Luteolin was thought to be the cause of this increase in activity, 
since a literature search at the time indicated that it was the only compound to have 
previously been shown to display estrogenic activity via both ER subtypes [23,30,42,54,55]. 
However, when the 7 individual phenolic compounds were tested at increasing concentrations 
(10x and 100x their concentration in F3), both mangiferin and luteolin displayed significant 
(P<0.001) ERβ agonist activity at higher concentrations (100x). In fact mangiferin already 
display significant activity at 10x its concentration (Figure 5.3). 
At this stage of the study, not much was known about mangiferin’s phytoestrogenic activity, 
and the ER mediated mode of action of both estrogenic phenolic compounds was investigated 
further. Both mangiferin and luteolin displayed binding activity to both ER subtypes and their 
transactivation via both ER subtypes was significantly antagonised by ICI 182,780 
(fulvestrant), indicating that their estrogenic activity is mediated via the ER (Figure 5.4 & 
5.5). To our knowledge, mangiferin’s ERβ mediated activity is a novel finding, with literature 
only presenting ERα related activity [68,73]. 
To understand the contribution of mangiferin and luteolin to the ERβ activity of F3R (100x), 
both ‘addition’ and ‘subtraction’ studies were conducted. Addition studies entailed 
reconstituting mangiferin and luteolin at 100x their concentration in F3R, separately (Figure 
5.7) as well as combined (Figure 5.8), and with or without the other phenolic compounds at 
1x their concentration in F3R. From these results it became clear that, even though luteolin 
and mangiferin were the only two estrogenic compounds in F3R, they were not the only 
contributing factor to the ERβ mediated activity of F3R (100x), since their individual 
activities were significantly lower than that of the reconstituted fraction, F3R (100x). For 




example, mangiferin (100x) was a significant (P<0.01) 2-fold lower than F3R Man (100x) 
and F3R (100x) via ERβ (Figure 5.8 B). F3R 100x (Man & Lut), on the other hand, displayed 
no significant difference compared to F3R (100x), F3R Man (100x) or F3R Lut (100x), 
indicating that the concentration of the two estrogenic phenolic compounds in F3R (100x) are 
interchangeable, and that either one at 100x their concentration, in combination with the rest 
of the phenolic compounds, will produce the same response as F3R (100x). 
With subtraction studies (Figure S.4), each phenolic compound was “subtracted” from F3R 
(100x) by individually adding them at 1x their concentration, while the rest of the phenolic 
compounds were reconstituted at 100x their concentration in F3R. By doing this, we had 
expected to identify which of the non-estrogenic phenolic compounds in F3R contributed to 
the activity of the estrogenic phenolic compounds. Unfortunately, at this stage of the study, 
mangiferin lost its estrogenic activity, and luteolin appeared to be the only remaining active 
and contributing component in F3R, with no significant difference between luteolin (100x) 
and F3R (100x) (Figure S.4). Possible synergistic activity could, therefore, not be determined 
(Figure 5.9). 
Different stocks of mangiferin (26/09/14, 25/10/14, 07/04/15 and 16/06/15) were tested to 
determine if degradation of the compound had occurred, however, no structural change was 
detected via LC-MS (Figure S.5) and NMR (Figure S.6) studies. On the other hand, 
homomangiferin was also detected in the mangiferin stocks (Figure S.5 & Figure S.7). Plant 
sources that are used to isolate mangiferin, for example Mangifera indica or Rhizoma 
anemarrhenae, also contains other xanthone glucosides such as isomangiferin, 
homomangiferin and neomangiferin [60,88–90,117,118]. Furthermore, mangiferin also 
produces more than 20 possible metabolites, which begs the question if there were other 
undetected metabolites in the mangiferin sample [73,88,119]. In a recent study by Wilkinson 
et al. [73], for example, norathyriol (a putative metabolite and aglycone derivative of 




mangiferin [119,120]) showed strong phytoestrogenic activity via both ERα and ERβ, and 
was able to reduce MCF-7 cell viability, in contrast to mangiferin, which was only able to act 
via ERα. 
Furthermore, the modification in the medium preparation protocol should also be considered 
as a possible factor involved in the change observed in mangiferin (Figure 5.9) and 
consequently F3R’s activity (Figure S.4). Medium preparation instructions and suggested 
sodium bicarbonate concentration were obtained from the manufacture’s protocol. Although 
the pH of the medium was adjusted to 7.2 during preparation, it came to our attention that 
long storage of pre-made medium has resulted in a pH increase (pH≥9). Upon further 
investigation, it became apparent that the buffer capacity of the suggested sodium bicarbonate 
concentration is ideal for a 10% CO2 incubator (although not specifically stated by the 
manufacturer) and not for a 5% CO2 incubator, as used in our facilities. The buffer capacity 
could also not compensate for the lower atmospheric CO2 (0.04%) captured in the bottle 
when sealed, resulting in a gradual pH shift during storage. The sodium bicarbonate 
concentration was since adapted to compensate and prevent this pH increase during storage, 
especially since cells are sensitive to the cell culture environment and external factors such as 
pH [74–77,121].  
In addition to affecting cell behaviour, variation in pH levels can also affect 
phytocompounds, particularly phenolic acids [76,81,82,122–124]. Phenolic acids are 
renowned for their role in food quality and colour, and have beneficial antioxidant properties, 
but have been shown to be less stable in alkaline environments and maybe converted from an 
antioxidant to a pro-oxidant [49,81,82,123–126]. In the current study, two of the 7 major 
phenolic compounds in F3R are phenolic acids, namely protochatechuic acid and p-coumaric 
acid. In a study conducted by Chethan et al. [124], the phenolic acid content of their 
polyphenol rich seed coat fraction (PRSCF), which also included protocatechuic acid and p-




coumaric acid, decreased with increasing pH levels. Furthermore, a pH-induced shift in the 
ultraviolet absorption spectra of phenolic acids were noticed, which is an indication of 
compound instability and is influenced by the nature of the compound and it surroundings 
[81,124]. pH drifting could also affect hydroxyl groups in other phenolic compounds, such as 
mangiferin, which contains four aromatic hydroxyl groups [63,81,85]. For example, a recent 
study by Mendoza-Sarmiento et al. [85], demonstrated the deprotonation of mangiferin’s four  
hydroxyl groups between pH 7 and 9.6, which consequently increased mangiferin’s peroxyl 
radical scavenging activity. 
To conclude, the findings from the current study, as well as from other studies, reveals the 
complexity of plant extracts and further supports the argument that taking F3 apart may not 
be the ideal approach to investigating its possible synergistic mechanisms of action [7,16–
19]. It is evident that the minor phenolic compounds play a crucial role in F3 and F3R’s 
estrogenic activity, either by directly contributing to the estrogenic activity or more probably 
by creating a supportive environment for the estrogenic phenolic compounds. Further 
research is, however, needed regarding the influence of pH on F3R, the contributions of the 
minor phenolic compounds, and if mangiferin’s activity is influenced by deprotonation.   
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5.5. Supplementary Data 
 
Figure S.1: LC-ESI-MS chromatogram of F3 (A) and F3R (1x) (B) in positive ion mode. Comparing peaks 
of phenolic content in F3 and F3R (1x). F3R (1x) was reconstituted using 5 major phenolic compounds: 
mangiferin (2), isomangiferin (3), scolymoside (4), p-coumaric acid (elutes with other compounds) & 
protocatechuic acid, and 2 minor phenolic compounds: iriflophenone-3-C-glc (1) & luteolin (5).  
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Figure S.2: LC-ESI-MS chromatogram of F3 (top) and F3R (1x) (bottom) in positive/negative ion mode. 
Comparing peaks of individual phenolic compounds in F3 and F3R: (A) mangiferin & isomangiferin, (B) 
scolymoside
**
, (C) luteolin, (D) iriflophenone-3-C-glc
§
, (E) protocatechuic acid & (F) p-coumaric acid. 
                                                          
**
 The concentrations of the phenolic compounds were previously determined by Mortimer et al. [33][39], 
however, at the time there were no authentic standards for scolymoside and iriflophenone-3-C-glc, and these 
compounds were quantified relative to luteolin and iriflophenone-3-C-glucoside (isolated from Cyclopia 
genistoides), respectively. 
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Figure S.3: Promotor reporter studies comparing the activity of F3R (10x) to the newly reconstructed 10x 
fractions, via ERα (A) and ERβ (B) transactivation in agonist mode. HEK293 cells were transfected with 





F3R (10x), F3R mangiferin 10x, F3R isomangiferin 10x, F3R scolymoside 10x, F3R luteolin 10x, F3R 
iriflophenone-3-C-glucoside 10x, F3R p-coumaric acid 10x and F3R protocatechuic acid 10x. Statistical 
analysis: One-way ANOVA with Dunnett’s Multiple Comparisons Test as  post-test, all columns compared to 
solvent control set to 1 (black bar),*P<0.05, **P<0.01, ***P<0.001, or newly reconstituted 10x fractions 

















+ other polyphenols at 100x (F3R)
































Figure S.4: Promoter reporter studies investigating the effect of subtraction of phenolic compounds from 
F3R (100x) via ERβ transactivation in agonist mode: HEK293 cells were transfected with pSG5-hERβ, 
ERE.PS2.luc and a pGL2 basic empty vector, and induced with luteolin (100x), F3R (100x) and subtracted F3R 
(100x)’s, which consist of 6 phenolic compounds at 100x their concentration and one compound at 1x its 
concentration, respectively. Statistical analysis: One-way ANOVA with Dunnett’s Multiple Comparisons Test 
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Mangiferin: R = OH  
Homomangiferin: R = OCH3 [89] 
  







Figure S.5: LC-ESI-MS chromatogram in negative ion mode (A - C), TOFMS spectra (D & E) and UV 
spectra (F & G) of mangiferin analytical standard stocks. Mangiferin stocks were labelled according to 
receiving date: (A) 26/09/14, (B) 25/10/14 & (C - G) 07/04/15, and both mangiferin (1) and homomangiferin (2) 
were detected in all the mangiferin stocks tested. TOFMS analysis of mangiferin stock (07/04/15) validates the 
presence of both (D) mangiferin (Mr 422,33g/mol, C19H18O11) and (E) homomangiferin (Mr 436,37g/mol, 
C20H20O11).  UV-visible absorption data of (F) mangiferin and (G) homomangiferin correspond with findings 



































































































Figure S.6: 400 MHz 
1
H-NMR spectra (25 °C, DMSO-d6,) of mangiferin stocks. (A) NMR spectra of 
different stocks of mangiferin labelled according to receiving date: (1) Geldeblom et al., 2016, (2) 16/06/15, (3) 
16/06/15
*
, and (4) 07/04/15. Unknown signals detected at (c) 13.69 ppm and (d) 3.87ppm in samples 2 - 4. (B) 
Sample 1: mangiferin isolated and purified from Cyclopia by Gelderblom et al., 2016 (unpublished). No signals 
observed at position (a) 13.69 ppm and (b) 3.87ppm in sample 1. (C) Sample 2: mangiferin from Mangifera 
indica (16/6/15)
*
. (D) Sample 3: mangiferin analytical standard (16/6/15). (E) Sample 4: mangiferin analytical 

















Mangiferin analytical standard (3) 16/06/15 








Figure S.7: 400 MHz 
1
H-NMR spectra (pyridine-d5) of homomangiferin. (A) NMR spectra of 
homomangiferin in sample 3, mangiferin analytical standard (16/6/15). Signals detected at 3.7 ppm and 3.6 ppm 
was identical to the methoxyl (OMe) chemical shift found in Wu et al. [88]. (B) NMR temperature ramp of 
sample 2 at 80, 50 & 20ºC. (C) Temperature ramp shows coalescence of duplicated OMe signals (3.7 & 3.6 
ppm) at 80 ºC, confirming the presence of homomangiferin. 
 
C 20 ºC-cooled 80 ºC 
50 ºC 20 ºC 
Homomangiferin duplicated 
OMe’s signals 




Chapter 6: Final Discussion and Conclusion  




Cancer is a multifaceted disease characterised by abnormal and uncontrolled cell growth and 
division due to genomic mutations, which results in ineffective cellular repair and/or delayed 
apoptosis of defaulted cells [1,2]. Cancer accounts for approximately 13% of all deaths 
worldwide, and has a socio-economic impact on both developed and developing countries [2–
11]. Despite considerable progress made in cancer research (understanding cancer biology, 
identifying risk factors, early detection, accurate diagnosis and improved or novel therapies), 
there are still various limitations such as drug resistance, toxicity, and high costs associated 
with cancer therapies, with no definite cure for this disease [9,12,13]. The fight against cancer 
is complicated by the fragility of cells and the complex molecular network they form part of 
[14–16]. Furthermore, each cancer is unique to the host as a result of genetic and epigenetic 
changes caused by lifestyle and environmental factors [1,17–20].   
There are various risk factors that contribute to cancer incidence and mortality.  Interestingly, 
only 10% of these risk factors are due to inherited genetic defects, whereas 90% of cancer-
causing risk factors are lifestyle choices and environmental factors (Figure 6.1), including but 
not limited to tobacco smoking, alcohol consumption, diet low in nutrients, obesity, 
environmental pollution, oncogenic viruses, and exposure to UV, radiation and/or 
carcinogenic compounds [9,16,17,21–25]. Therefore, 30-40% of most cancer types can be 
prevented with a healthy lifestyle and dietary modifications [23–29]. Various epidemiological 
studies have linked diets high in plant based foods*, which are rich in dietary fibre, vitamins, 
minerals, antioxidants and phenolic compounds, to disease prevention and improved health 
[27–38]. 
 
                                                          
*
 Plant based foods include fruit, vegetables, whole grains, nuts, legumes and herbs [30,31,38]. 













Figure 6.1: Cancer-related risk factors as adapted from Anand et al., [23].  
In addition to using plants as a source of health promoting macro–and micronutrients, various 
cultures and societies are also dependant on plants for medicinal purposes [38–42]. Some of 
the poorer or lower–income countries lack proper health care systems, medical facilities and 
pharmaceutical manufacturing capacity to provide safe and affordable medical care [43–45]. 
Consequently, the native communities rely predominantly on alternative phytomedicine and 
traditional practices [40,42,46–48]. It has been estimated that 70-80% of African countries 
use some form of traditional or complementary/alternative medicine (CAM)†, either as 
primary source of treatment or to alleviate side effects associated with some conventional 
therapies, such as in the case of HIV/AIDS treatments [43,49,50]. 
Various pharmaceutical and nutraceutical products come from medicinal plants and plant 
extracts. Generally, the plants are selected for specific favourable properties and the main 
active compounds are isolated, characterised and synthesized for target specific drug 
therapies [39,51,52]. Examples of such pharmaceutical drugs originating from plant sources 
                                                          
†
 Complementary and alternative medicine (CAM) is a term used for medicinal products or practices that are not 
part of conventional medicine, but are often used together with (complementary) or instead of (alternative) 
conventional medicine [124]. 
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include: aspirin (Filipendula ulmaria), codeine and morphine (Papaver somniferum), which 
are used as analgesics, artemisinin (Artemisia annua), which is used as an anti-malaria drug, 
and galantamine (Galanthus nivalis), which is used for the treatment of Alzheimer's disease 
[41,53–56]. Although single well-characterised active compounds work effectively in treating 
particular diseases, they show less effectiveness in the treatment of multifaceted diseases, 
such as cancer, and in some case result in drug resistance [57,58].  
Whole plant extracts and combination phytotherapies, on the other hand, consist of multiple 
constituents (active and supporting) and can therefore display multiple actions [59]. In the 
plant, the mixture of different phytocompounds works together in a combinatorial or 
synergistic manner to create a supporting environment for the active compounds, as well as 
enhancing their bioactivity [31,59–62]. Furthermore, plant extracts have the potential to 
interact with multiple biological targets and systems, for example, Salacia oblonga extracts, 
which are used in Ayurvedic medicine for the prevention and treatment of type 2 diabetes, 
also displays anti-proliferative activity in MCA-MB-231 breast cancer cells [59,63–65]. In 
addition, within each biological system the phytocompounds may direct their activity at 
various intracellular targets and intervene with different cell signalling processes [63,66,67]. 
This multi-target action of medicinal plants and their extracts provides renewed insight into 
combatting complex diseases and could perhaps supply an intelligent drug mixture able to 
combat cancer on multiple levels [62,68]. However, much is yet to be learned about the 
complex networks and synergistic interactions within plant extracts. 
Our research group focus specifically on breast cancer, the most common diagnosed cancer 
amongst women [69–71]. Genetic factors account for 5-10% of all breast cancer cases with 
mutations in genes such as BRCA1, BRCA2, P53, ATM, PTEN/MMAC1 and LKB1 
resulting in greater genetic susceptibility for breast cancer [72–75]. Other risk factors 
associated with breast cancer include alcohol consumption, obesity, diet, and exposure to 




radiation,  in addition to hormone related risk factors (early menarche, the use of hormone 
contraceptives, late pregnancy of first child, and  late menopause), which increases the risk of 
estrogen receptor (ER) positive breast cancer, the most common type of breast cancer 
[9,22,23,26,69,73,76].   
Estrogens (endogenous and exogenous) are the main driving force behind ER positive breast 
cancer, however, estrogens also play a vital role in the development and function of the 
female reproductive system as well as in bone maintenance, cardiovascular protection and 
cognitive functioning [77–82]. Therefore, the use of exogenous estrogens, as in the case of 
menopausal hormone replacement therapy, provides both a protective role (prevention of 
osteoporosis, cardiovascular diseases and mental diseases) and a harmful role (increased risk 
of estrogen related cancers, such as breast cancer), thus creating a double edged sword 
scenario where woman are at risk for one group of diseases if they do not take hormone 
replacement therapy, and at risk for another group of diseases if they do [77–85]. For this 
reason, women are seeking alternative forms of hormone therapies and are turning to plant 
extracts high in phytoestrogens, since they are deemed as safer and more natural sources of 
estrogens [86–90]. These plant extracts should, however, still be used with caution, since the 
combination of all the different constituents, including the phytoestrogens, are not as well 
studied as conventional hormone therapies [91].  
The goal of our research group is to develop a potential nutraceutical that reduces 
menopausal symptoms and related diseases, while decreasing the risk of developing estrogen 
related cancers, specifically breast cancer. One plant of particular interest for us regarding 
possible novel nutraceutical or pharmaceutical development is Cyclopia, an indigenous South 
African fynbos plant more commonly known as honeybush [92–95]. Cyclopia contains high 
levels of phenolic compounds and has, in various studies, displayed phytoestrogenic, anti-




diabetic, anti-inflammatory and anti-mutagenic activity [94–100]. Unlocking the 
pharmaceutical potential of Cyclopia could also be beneficial to South Africa’s economy. 
The sequential methanol extract from Cyclopia subternata (SM6Met) has shown promising 
in vitro and in vivo results in different breast cancer experimental systems and models [100–
102]. The desired estrogenic characteristics of this extract include ERα antagonism and ERβ 
agonism (which is important in ER positive breast cancer therapies since ERα is known to 
induce cell proliferation, whereas ERβ has shown to antagonise ERα mediated activity), and 
inhibition of E2-induced breast cancer cell proliferation [100–106]. To evaluate the multi-
target potential of SM6Met, Mortimer et al. fractionated the extract and found that the 
phenolic content as well as favourable estrogenic profile of SM6Met was divided between the 
three fractions, with F1 and F2 displaying ERα antagonism and F3 displaying robust ERβ 
agonism, thus reaffirming the importance of the whole extract [107]. Mortimer also identified 
some of the phenolic compounds in the different fractions, however, the combinatorial or 
possible synergistic activity of all the different phytocompounds has never before been 
investigated. The current study continued on from Mortimer’s work, and as a starting point, 
focused specifically on F3 and the 7 major phenolic compounds quantified in this fraction 
from amongst the 15 phenolic compounds identified by Mortimer et al. [107]. 
The first aim of the current study was to establish an experimental system sensitive enough to 
detect small drug induced changes. Following on from Mortimer’s study, the same in vitro 
experimental systems were used (promoter reporter assay using HEK 293 cells and 
proliferation assay using MCF-7 BUS cells). Various factors were investigated including cell 
types, the ER subtypes combined with different ERE promoter reporter constructs, and the 
optimisation of the experimental procedures, after which is was established that the promoter 
reporter assay (post-optimisation), is a more sensitive experimental system to test 
phytocompound interactions. Specifically, optimisation resulted in a significant (P<0.001) 9-




fold increase in the efficacy of E2 via ERβ, with no significant increase via ERα. Despite the 
difference in efficacy between ERα and ERβ, the increase in sensitivity via ERβ is a more 
desired outcome since F3 is characterised as a robust ERβ agonist. 
The second aim entailed the reconstitution of F3 (F3R) using the 7 major phenolic 
compounds (mangiferin, isomangiferin, scolymoside, luteolin, iriflophenone, p-coumeric acid 
and protocatechuic acid)
‡
 as identified and quantified by Mortimer et al. [107],  to investigate 
their contribution to the robust ERβ activity of F3. Interestingly, F3R displayed no significant 
estrogenic activity with the 7 major phenolic compounds at 1-fold their concentration in F3. 
Possible reasons for the lack of estrogenic activity could be that the excluded phenolic 
compounds in F3 (alone or combined) are responsible for F3’s estrogenic activity, or that 
they create a supporting environment for the active compounds to elicit a response. However, 
when F3R was reconstituted at 100-fold (F3R (100x)) its concentration, a significant 
(P<0.001) increase in activity was observed via both ERα and ERβ, indicating that some of 
the phenolic compounds in F3R do possess estrogenic activity. It was initially though that 
luteolin was the cause of the increase in estrogenic activity observed with F3R (100x), since, 
at this stage of the study, it was the only phenolic compound out of the 7 that had in previous 
studies displayed phytoestrogenic activity via both ER’s [95,96,108–110].  
The next step (Aim 3) was to investigate the estrogenic activity of the individual phenolic 
compounds in F3R, to establish which of the compounds are, in fact, the active estrogenic 
compounds. As expected, luteolin displayed estrogenic activity at increased concentrations 
via both ERα and ERβ, mangiferin, however, also displayed estrogenic activity at increased 
concentrations, via both ER subtypes. A detailed investigation of the estrogenic activity of 
these two estrogenic compounds, confirmed mangiferin and luteolin’s ER mediated mode of 
action. To our knowledge, mangiferin’s ERβ mediated activity is a novel finding, with 
                                                          
‡
 Phenolic compounds were purchased. See section 3.2.1. 




literature only recently presenting ERα related activity in different experimental systems 
[111,112]. 
After establishing that mangiferin and luteolin were the only two estrogenic phenolic 
compounds in F3R, addition and subtraction studies (Aim 4) were conducted to investigate 
the supporting role of the 5 non-estrogenic phenolic compounds (in combination with the 2 
estrogenic phenolic compounds) in the estrogenic activity of F3R (100x). This was 
necessitated as mangiferin and luteolin’s individual estrogenic activity (at 100x their 
concertation in F3R) was still significantly lower than that of F3R (100x).  In the addition 
studies, mangiferin and luteolin displayed interchangeable activity in F3R (100x) via ERβ, 
with no significant difference between F3R (100x) and the newly reconstructed fractions 
(F3R Man (100x), F3R Lut (100x) & F3R 100x (Man + Lut)). This further accentuates the 
importance of the non-estrogenic phenolic compounds in F3R (100x), and suggests that the 
non-estrogenic phenolic compounds, even at 1x their concentration in F3R, enhance the 
activity of the estrogenic phenolic compounds. Via ERα, these newly reconstructed fractions, 
however, displayed significantly lower activity compared to F3R (100x), indicating that one 
or more of the non-estrogenic phenolic compounds are needed, at 100x their concertation, in 
order to recreate F3R (100x)’s activity. Aim 4, however, could only be completed in part, 
since, with the subtraction studies, mangiferin lost its estrogenic activity and luteolin 
appeared to be the only contributing factor to the activity of F3R (100x). Consequently, the 
last aim could also not be completed and the combinatorial or possible synergism activity of 
the 7 major phenolic compounds could not be determined. 
An additional investigation was conducted to determine the possible cause for the sudden loss 
of mangiferin’s activity. Various mangiferin stocks were tested and no structural changes or 
degradation of the phenolic compound was detected via LC-MS and NMR studies, however, 
homomangiferin was detected in all the mangiferin stocks used for experimental work. Like 




mangiferin, not much is known about homomangiferin’s estrogenic mode of action. Another 
possible cause was speculated to be external factors such as pH, since pH drifting has been 
shown to be responsible for deprotonation of hydroxyl groups in phenolic compounds, 
including mangiferin [113–115]. Further investigation is, however, needed regarding the 
influence of pH drifting on F3R activity. 
To summarise the findings from the current study, F3’s robust ERβ agonist activity could not 
be recreated using only the 7 major phenolic compounds quantified in this fraction, and it is 
apparent that the minor phenolic compounds play a crucial role in the desired estrogenic 
profile of this fraction. Even though the major phenolic compounds showed no estrogenic 
activity (individual and combined) at their concentrations in F3 (F3R (1x)), their contribution 
to this fraction’s activity, and subsequently the multi-target activity of SM6Met, should not 
be dismissed. In a review article by Gertsch [62], the author describes the possibility of 
weaker or non-active secondary metabolites in plant extracts to still exert an effect in the 
absence of the bioactive compounds due to biochemical synergism or network pharmacology. 
When F3 was reconstitution with the 7 major phenolic compounds at 100-fold their 
concentration in F3, a significant (P<0.001) increase in activity was observed via both ER 
subtypes. Upon further investigation, it became clear that the two estrogenic phenolic 
compounds, mangiferin and luteolin, were not the only contributing factors to F3R (100x)’s 
robust estrogenic activity, and the non-estrogenic compounds potentially played a supporting 
role in the bioactivity of this fraction. Various studies have presented similar results where 
the isolated active phytocompounds showed less effectiveness or a decrease in bioactivity 
compared to the plant extract [62,68,116–119]. In addition, mangiferin’s ERβ mediated 
activity was a novel finding, unfortunately, mangiferin lost this activity during the final 
stages of the current study. Future work should investigate the contribution of the minor 
phenolic compounds in F3 to the favourable attributes of this fraction, in order to establish 
which phytocompounds to target for the investigation of combinatorial or possible synergistic 




interactions. In silico (computational) methods could also aid in identifying potential 
synergistic phytocompounds, by means of virtual screening of natural chemical libraries such 
as DrugBank, Asinex, ZINC databases, in combination with drug synergy software such as 
Compusyn and Combenefit  [66,120–123]. 
Plants may provide us with future intelligent drug mixtures, with the possibility of 
overcoming the limitations of current therapies, however, a great deal is yet to be discovered 
regarding the complex interactions of phytocompounds. Like the game of Jenga, removing 
vital phytocompounds from the mixture creates instability, and eventually results in the 
collapse of the complex multi-target system. 
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